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Abstract 
In this thesis, emphasis is given to the study of temperature-responsive systems and their use 
in drug and gene delivery applications. 
Studies on polymer-surfactant systems were conducted, using amino acid-based surfactants. 
In these studies, ethyl (hydroxyethyl) cellulose (EHEC) was the investigated polymer, while 
the interactions with six different surfactants were analyzed. Three of these were anionic 
and lysine-based, having a gemini-like structure and different alkyl chain length. In 
addition, three cationic arginine-based surfactants were investigated. Of these, two had a 
gemini structure, while the third was monomeric. 
The polymer-surfactant systems were characterized in terms of their rheological properties, 
i.e. complex viscosity, gel points, gel properties and thermodynamic features in form of 
cloud points. It was shown that the mixtures were generally low viscous at room 
temperature, and that the viscosity increased at higher temperatures, in agreement with the 
formation of a polymer network stabilized by hydrophobic associations and electrostatic 
repulsions. Sol-gel transitions were also observed, suggesting that the gels could be 
employed as pharmaceutical formulations undergoing gelation in situ, once injected.  
Importantly, surfactants with long alkyl chains and gemini-like structure were the most 
efficient, which implies that very low amounts are needed in order to induce the sol-gel 
transition at elevated temperatures.  
The biocompatibility of the EHEC-surfactant systems was evaluated by performing in vitro
experiments on a human cell line (HeLa cells). These studies revealed that the higher 
toxicity of the long-chain/gemini-like surfactants was significantly compensated by their 
superior efficiency at low concentrations. 
Experiments were further carried out with the intention of developing a microparticulate 
system for controlled drug delivery. An emulsification-solvent evaporation method was 
employed according to a planned experimental design that aimed at evaluating the process 
parameters on the size properties of the microparticles. Chitosan, a hydrophobically-
modified chitosan derivative (HM-chitosan) and poly lactic-co-glycolic acid (PLGA) were 
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investigated as the polymeric matrix. The blank microparticles were characterized in terms 
of size and size distribution. Following the multivariate analysis, specific parameters were 
chosen to produce the drug-loaded microparticles. Naltrexone, an opioid antagonist, was 
used as the model drug. The microparticles were evaluated in terms of their morphological 
properties (scanning electron microscopy), and the drug encapsulation efficiency and 
loading capacity were determined. In vitro drug release experiments were carried out. The 
results from this study showed that HM-chitosan microparticles were recovered in a high 
yield and that the encapsulation efficiency was higher as compared to the use of the other 
polymers. Importantly, this polymer also demonstrated the higher capacity to retain the 
drug, which was slowly released for at least 50 days.  
Finally, four cationic temperature-responsive block copolymers were evaluated as gene 
carriers. These polymers had a structure based on poly (N-isopropylacrylamide)-block-
poly((3-acrylamidopropyl) trimethylammonium chloride) (PNIPAAM-b-PAMPTMA(+)), 
and were distinct in terms of the length of the blocks. Complexes between polymer and 
plasmid DNA were prepared at different polymer/DNA ratios, and used to transfect HeLa 
cells. Because the plasmid DNA coded for green fluorescent protein (GFP), the expression 
of this protein was followed by flow cytometry. Cell viability studies were simultaneously 
carried out in order to evaluate the cytotoxic effects of the complexes. The results showed 
that polymers with longer PNIPAAM or shorter PAMPTMA(+) were the most effective 
carriers. A series of physicochemical experiments were carried out (dynamic light 
scattering, zeta potential and turbidity), so as to gain insights into copolymer structure-
activity relationships. It was shown that the most effective carriers had a compact 
PNIPAAM core that collapsed at 37 °C surrounded by a positively charged corona. 
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6Lys6, 8Lys8, 10Lys10 Lysine-based surfactants with gemini-like structure and different 
chain length (6, 8 or 10 carbon atoms, respectively) 
C6(LA)2, C9(LA)2 Gemini lauroylarginine surfactants with different spacer length (6 
or 9 carbon atoms, respectively) 
cac Critical aggregation concentration 
cmc Critical micelle concentration 
DDSs Drug delivery systems 
CP Cloud point 
CTAB Cetyl trimethylammonium bromide 
df Fractal dimension 
EE Encapsulation efficiency 
EHEC Ethyl(hydroxyethyl) cellulose 
GP Gel point 
LAM NĮ-lauroyl-L-arginine methyl ester (or the monomeric arginine-
based surfactant) 
LCST Lower critical solution temperature 
MESC Minimum effective surfactant concentration inducing gelation of 
EHEC semidilute solutions 
N/P Polymer nitrogen-to-DNA phosphate (+/-) charge ratio 
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PAMPTMA(+)m
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1 Introduction 
1.1 Drug delivery systems 
In classical drug delivery formulations, the drug is typically administered by the oral, 
subcutaneous, intramuscular, intravenous and topical routes, and the plasma drug 
concentration corresponds directly to the administered dose. In other words, the drug is 
released relatively fast, often requiring several administrations for a therapeutic effect 1, 2. A 
fast drug release also produces high plasma levels, causing adverse effects and 
compromising patient compliance 2, 3. 
Controlled drug delivery systems (DDSs) have been developed in order to circumvent the 
main limitations of conventional formulations. Advanced systems based on lipids such as 
liposomes and solid lipid nanoparticles 4-6 have been widely studied over the years. The high 
versatility and stability of polymers, also make these very useful materials in drug delivery 
applications, and a number of polymer-based systems such as micro and nanoparticles 7-9, 
hydrogels 10-12 and films 13 have been extensively investigated as substitutes for the classical 
formulations. 
The modern DDSs aim at delivering appropriate amounts of the drug to the intended site, at 
an appropriate rate, while also minimizing local and systemic toxic effects 1, 14. DDSs can 
also protect the drug from physiological degradation and elimination and increase its 
circulation time 15. This is especially relevant for pharmaceuticals such as proteins and 
peptides that get easily deactivated and destroyed when administered orally, and are rapidly 
eliminated after intravenous injection 1, 16.  
The poor water solubility of hydrophobic drugs can be a challenge that compromises the use 
of many investigated compounds 17.  When this is the case, using nanoscale delivery 
systems can significantly help to improve the drug solubility and increase their 
bioavailability 17, 18.   For instance, low solubility drugs (e.g. paclitaxel, tamoxifen) have 
been incorporated into nanoparticles 19, 20 and liposomes 21, in order to improve their 
efficacy. 
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DDSs also have the possibility of targeting a specific site. The absorption of the drug at the 
target tissue or organ can also be considerably improved, contributing to the maintenance of 
therapeutically appropriate doses 1. From a commercial point of view, the use of controlled 
delivery technology may additionally be advantageous since formulating marketed drugs 
into new pharmaceutical forms can result in patent extension 15.  
1.1.1 Pharmaceutical and biomedical applications of DDSs 
In the challenging field of cancer therapy, DDSs can offer an essential contribution to 
improve the efficacy of the treatment. The literature concerning the design and properties of 
new systems that are able to deliver the cytotoxic drugs to tumor sites is therefore very 
extensive 22-24. The motives for the high interest of DDSs in cancer therapy can be explained 
briefly as follows. First of all, DDSs can alter the typical pharmacokinetics and 
biodistribution profiles of the chemotherapeutic drugs, thereby improving their 
pharmacological  properties 22. The fact that the cytotoxic drugs are protected within a 
carrier, allows the presence of high drug concentrations while minimizing the systemic 
toxicity 22, 23. Furthermore, DDSs in cancer therapy provide the possibility to reach the 
tumor site, using passive or active targeting strategies. Passive targeting takes advantage of 
the leakiness of tumor blood vessels (the so-called ‘enhanced permeability and retention 
effect’ or EPR effect), by using nano-sized DDSs that can be taken up and accumulated in 
tumor tissues. Active targeting is more specific and requires functionalization of the carriers 
with surface ligands that bind to receptors overexpressed on the tumors or associated 
endothelium 22, 23. With respect to the next generations of DDSs for cancer treatment, 
scientists seem to agree that developing combinatorial or multifunctional ‘smart’ carriers 
may provide the best results. Another promising strategy is to develop personalized and 
tailor-made systems 22-24. 
In many other applications, the main role of the DDS is to release the loaded drug at a slow 
rate, allowing for the reduction of the number of administrations. Systems resulting in a 
long-lasting effect have been developed for the treatment of tuberculosis 25, retroviral 
infection 26, Parkinson’s 27, 28 and other neurodegenerative  diseases 29, glaucoma 30 and also 
for tissue engineering applications 31. Controlled delivery systems based on the opioid 
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antagonist naltrexone have similarly been proposed for the treatment of alcohol and drug 
addiction 32, 33. By controlling the drug release rate, it is possible to ensure that the released 
amounts are within the therapeutic window for sufficiently long periods of time. In 
polymer-based systems, this can be achieved by modifying the polymer properties such as 
architecture, composition and molecular weight 34. From these DDSs, the drug can be 
released to the external medium by one or more mechanisms, including diffusion, matrix 
swelling, chemical degradation, dissociation or in response to external stimuli 16, 34.  
Gene therapy is considered an encouraging and progressing field for the treatment and 
prevention of genetic-based disorders 35, 36. In gene delivery, DDSs have been used in 
replacement of viral systems to deliver nucleic acids into the cell compartments, where the 
induction of gene expression or the silencing of specific genes results in a therapeutic effect 
35, 36. The carrier systems provide the nucleic acids with protection during blood circulation, 
condense them to an appropriate size and facilitate cell uptake. Once in the intracellular 
medium, the carrier also helps to deliver the payload into the target compartment 35, 37. Both 
cationic lipids and cationic polymers have been used to deliver the nucleic acids into the cell 
compartments. These systems and their mechanisms of action have been widely investigated 
in gene therapy and it has been shown that the chemical and supramolecular structure of the 
carrier has an important effect on the delivery efficiency 36. The subject of gene delivery and 
its challenges will be briefly introduced in section 1.5. 
In this thesis, emphasis will be given to polymer-based formulations and their potential 
applications as drug delivery systems for conventional drugs and nucleic acids. Because this 
project was firstly focused on the production of in situ-gelling systems for the sustained 
release of conventional drugs, an overview of hydrogels as DDSs will be presented. The use 
of stimuli-responsive systems in pharmaceutical and biomedical applications will similarly 
be described in the following sections. Particular attention will be paid to the temperature-
responsive ethyl(hydroxyethyl cellulose) (EHEC) that in combination with ionic surfactants 
produced low toxicity in situ gelling systems (Paper I-III). The use of polymer-based 
microparticles as controlled drug release systems will be addressed, since a depot 
formulation was also developed, with naltrexone being the encapsulated drug (Paper IV). 
Poly(N-isopropylacrylamide) (PNIPAAM), which was further investigated for gene delivery 
applications (Paper V), will be briefly introduced.
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1.2 Polymeric hydrogels 
Polymeric hydrogels are three-dimensional networks of polymer chains that are loosely 
cross-linked, enabling the system to entrap a high amount of water and causing the matrix to 
swell 38, 39. In the last years, these materials have been used in numerous applications, with 
special emphasis on the biomedical and pharmaceutical fields. In tissue engineering and 
regenerative medicine, hydrogels have shown to be promising materials for the repair of 
cartilage 40, 41, bone 42, 43 and soft tissue 44, 45, where they form scaffolds for cell growth and 
proliferation. The applicability in biomedical devices, such as films, sponges and biosensors 
is also recognized 46. In drug delivery, hydrogels have been widely used as depot systems, 
for instance through the oral 47, topical and transdermal 48, 49, gastrointestinal 50, 51, ocular 52, 
nasal 53, 54 and vaginal 55, 56 administration routes.  
Due to the high porosity of the hydrogels, high drug amounts can be loaded into the 
formulation 57. Drug release from hydrogels takes place mostly by diffusion, even though it 
can also depend on matrix swelling and chemical reactions (e.g. polymer chain cleavage by 
hydrolytic or enzymatic degradation) 58. Importantly, it considerably depends on the 
polymer composition (type of monomers and chain length), cross-link density, and 
type/intensity of the external stimuli 11, 58. Having this in mind, drug-loaded hydrogels with 
specific properties can be tailor-made in order to meet specific criteria, such as a slow 
release rate 58. A very interesting concept is the achievement of a delayed drug release, 
through chemical or physical interactions with the hydrogel matrix. In one approach, the 
charged drug can be formulated into an oppositely charged hydrogel, in order to promote the 
establishment of electrostatic interactions. Other strategies are to covalently link the drug to 
the polymer chains, thereby allowing a delayed release following hydrolytic or enzymatic 
degradation of the polymer-drug bonds; and to use specific polymers or monomers with 
high affinity for particular drugs 11. 
The attractiveness of hydrogels in biomedical and pharmaceutical applications for human 
use is closely related to their properties. In general, hydrogels are considered biocompatible, 
thereby not causing significant toxic effects once administered 11, 38, 58. The biocompatibility 
of a hydrogel can also be increased by including specific polymers in the composition, 
particularly those that exhibit similar properties to the extracellular matrix, e.g. the 
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hydrophilic polyethylene glycol (PEG) and some polysaccharides 57. The fact that the 
hydrogels can be formulated so as to mimic the viscoelastic properties of human tissues is 
actually one of their most appealing features. In a similar way, biodegradable hydrogels can 
be produced by using polymers that can be enzymatically or hydrolytically cleaved in the 
host environment 57. Moreover, the physicochemical characteristics of the hydrogels can be 
changed in order to fulfill the requirements of the intended use (e.g. adherence and 
deformation capacity) 10, 11. 
1.2.1 Hydrogel classification according to the cross-linking mechanism 
Hydrogels can be classified in different ways, namely according to the nature of the 
monomers (ionic or neutral), and according to the polymer structure. Quite often, hydrogels 
are also classified in relation to the type of cross-links involved, since this can have a 
significant effect on the swelling behavior, mechanical strength and deformation properties 
of the resulting hydrogels. In this classification, two types of cross-links are commonly 
described: the covalent or chemical, and the non-covalent or physical cross-links 38. 
Chemical gels, i.e. those prepared by the introduction of covalent cross-links into the 
network, are generally regarded as ‘irreversible’ gels. Hydrogels such as these can 
essentially be produced by irradiation or chemically-induced polymerization between 
components with reactive functional groups or by cross-linking agents. The chemical cross-
linking of the matrix can take place between polymers or copolymers, or between polymers 
and monomers or macromers in solution 57. One well-known example of a chemical gel is 
produced by chemically cross-linking poly(N-isopropylacrylamide) (PNIPAAM) with N,N’-
methylenebis(acrylamide). This example will be discussed in more detail in section 1.3.2. 
In physical gels, the polymer chains are not covalently linked, but are instead found 
entangled or associated by hydrophobic associations, electrostatic interactions or by the 
establishment of hydrogen bonds 12. Polymers that undergo gelation by hydrophobic 
bonding are typically amphiphilic and hence composed by hydrophobic blocks and 
hydrophilic segments. Often, hydrophobic side-chains are grafted to a hydrophilic 
backbone, or an amphiphilic block copolymer is produced 11. The physical gelation of these 
copolymers sometimes depends on temperature changes (see section 0 for information on 
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stimuli-responsive hydrogels). In this case, the increase in temperature triggers the 
association of the hydrophobic domains that respond in this way so as to minimize the 
contact with the bulk water 11.  
A sol-gel transition can also be observed when interactions take place between two 
oppositely charged polymers, or between a polymer and a small molecule of opposite 
charge 11. One well-known example of the latter is the gelation of alginate in the presence of 
multivalent cations such as Ca2+. Here, each divalent cation binds two glucuronic acid sites, 
linking the alginate chains together (forming cross-linking points), which results in the 
formation of a low flexibility network, i.e. in the formation of a hydrogel. Alginate 
hydrogels have been widely used in biomedical and pharmaceutical applications 12, 59, 60. 
Hydrogen bonds can also act as physical cross-linkers in block copolymers and 
homopolymers, forming interactions between polymer chains with compatible geometries 11, 
61. In this case, the intermolecular association of polymer chains through hydrogen bonds 
can lead to the formation of crystallites, which ultimately contributes to the formation of the 
hydrogels 61. Some examples of polymeric hydrogels stabilized by hydrogen bonding are 
dextran 61, polyvinyl alcohol 62 and blends of natural polymers such as gelatin-agar and 
hyaluronic acid-methylcellulose 11. Semidilute pectin solutions also form gels at low 
temperatures due to intermolecular hydrogen bonding 63. 
Physically cross-linked hydrogels are often considered biocompatible and biodegradable. In 
contrast, the presence of external cross-linkers in chemical gels, renders them more toxic 
and difficult to degrade 57. In spite of this clear advantage of the physical gels, particularly 
in what concerns their presence in formulations for human use, these are also more prone to 
dilutions at the administration site, and variables such as gelation time, pore size and 
degradation time are more difficult to control independently 11.  
Selected examples of gel systems that respond to temperature changes, such as the triblock 
copolymers PEO-PPO-PEO (Pluronic) and PLGA-PEG-PLGA will be briefly described in 
section 0, under the topic ‘Temperature-responsive polymers’. 
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1.3 Stimuli-responsive polymer systems 
In recent years, stimuli-responsive or ‘smart’ polymers have attracted great attention for 
drug delivery applications. These polymers respond to small changes in environmental 
conditions, such as temperature, pH, light, ionic strength, electric or magnetic fields, or the 
presence of enzymes or specific ligands 64. In addition, some polymer systems can combine 
more than one stimuli-responsive mechanisms, for example by responding to both pH and 
temperature changes 65, 66.  
In drug delivery, polymers that respond to pH variations or temperature changes are 
particularly interesting materials, since this ability to undergo reversible phase transition or 
conformational changes depending on the external environment can be used to promote the 
drug loading, and to modulate the rate and site of drug release 64.  
Some specific stimuli-responsive polymer systems will be discussed next, with particular 
emphasis being given to the applications of pH- and temperature-responsive polymers. The 
structures of some stimuli-responsive polymers are given in Figure 1. 
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Figure 1. Chemical structures of some polymers that respond to pH and temperature with applications in drug 
delivery.
pH-responsive polymers 
Polymers that respond to pH typically contain ionizable groups that can accept or donate 
protons in response to the environmental pH. In this case, changing the pH across the pKa
threshold of the polymer, results in a rapid change of its net charge and in the hydrodynamic 
volume of the polymer chains. In other words, the presence of a highly charged structure 
causes the matrix to swell as a result of the high charge repulsion, and as the polymer shifts 
from a collapsed state to an expanded state 67. The osmotic pressure created by the presence 
of the mobile counterions also helps to explain the increase in the hydrodynamic volume of 
the polymer chains 68. 
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It is particularly interesting to take advantage of the pH differences in the human body (e.g.
along the gastrointestinal tract) to achieve a targeted drug delivery by using polymers that 
respond to pH changes. In addition, in anti-cancer drug delivery, the release of the drugs can 
also be triggered by the acidic extracellular pH of the tumors, which contributes to a higher 
efficiency and lower toxicity to the surrounding tissues 69, 70. 
The polymer composition of a drug delivery system should thus be carefully considered, 
having in mind the specific aim. Poly (acrylic acid) (Figure 1), has been used in drug 
delivery systems that target the intestine 71. Due to the presence of ionizable COOH groups, 
this polyelectrolyte is protonated and thus uncharged at low pH and negatively charged at 
high pH. The presence of a protonated structure at low pH (as in the gastric environment) 
eliminates the electrostatic repulsion forces and contributes to the formation of a compact 
structure. The formation of a low flexibility network is also promoted by the formation of 
hydrogen bonds 68. When the pH is increased above the pKa of the polymer, the negative 
charges are dominant, and the high charge repulsion causes the network to swell or dissolve 
and release the drug. Accordingly, the drug can be released from poly(acrylic acid) matrices 
as a result of the higher pH (7.4) in the intestinal environment 68, 71. 
For other applications, one can specifically trigger the drug release in response to acidic 
environments. Polybases such as poly(N,N’-dimethyl aminoethyl methacrylate) 
(PDMAEMA) (Figure 1) and poly(ȕ-amino esters) have amino groups that are deprotonated 
at neutral pH but become positively charged by gaining protons at acidic pH 68. This is 
particularly relevant in cancer drug delivery, since the extracellular environment of solid 
tumors is weakly acidic (pH < 6.5), while the pH in the endosomes and lysosomes of cancer 
cells is even lower (pH 4.0-6.0) 72. In this context, particles formed by polybases are stable 
at physiological pH. However, in the tumor tissues or their intracellular compartments, the 
particles become positively charged and dissolve rapidly as a response to the lower pH, thus 
releasing the cytotoxic drug 73. In normal tissue, the slightly acidic environment of the 
endosomes can also be used to trigger the release of the payload in gene delivery 
applications 70, 74. Polyethyleneimine (PEI) and poly(L-lysine) (PLL) (Figure 1), are two 
well-known carriers in nonviral gene delivery 64. 
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Temperature-responsive polymers 
Due to their unique properties, polymers that respond to temperature changes are among the 
most investigated in modern drug delivery applications. Specifically, they are characterized 
by changing their conformation, solubility and hydrophilic/hydrophobic balance as a 
response to changes in the temperature of the external environment 64, 75. 
In drug delivery, in situ gelling systems are a particularly appealing concept. By using 
temperature-responsive polymers, one can for instance produce a low viscosity solution that 
can easily be injected but that undergoes fast gelation in situ as a response to body 
temperature.  
One example of polymers that undergo temperature-induced gelation are the ABA-type 
triblock copolymers poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) 
(PEO-PPO-PEO, also known as Pluronics/Poloxamer) 68, 76. As the temperature is increased, 
the PPO blocks associate through hydrophobic interactions, which leads to the formation of 
micelles with a PPO core and a hydrophilic PEO corona. It has been hypothesized that at 
sufficiently high concentrations, the micelles arrange in a packed, entangled structure (such 
as cubic crystalline phase), creating a three dimensional structure, i.e. a gel 77. This sol-gel 
transition strongly depends on the hydrophilic-hydrophobic balance and on polymer 
concentration. Under specific conditions, the transition can take place close to physiological 
temperature, allowing in situ gelation 68. At even higher temperatures, the gel becomes an 
opaque solution (cloud point, CP), due to the shrinkage of the PEO corona and higher 
interactions with the PPO core 78. 
In spite of generally being regarded as biocompatible, PEO-PPO-PEO block copolymers 
have some important drawbacks that may limit their applicability, such as their weak 
mechanical strength, rapid dissolution and non-biodegradability. However, specific 
synthetic strategies have been discussed in order to circumvent these issues 77.  
Poly(ethylene glycol)-b-poly(lactide-co-glycolide)-b-poly(ethylene glycol) (PEG-PLGA-
PEG) was designed for an improved durability and biocompatibility 78-80. As in the case of 
Pluronics, a sol-gel transition can also be observed when the temperature of PEG-PLGA-
PEG solutions is increased. In this case, it is hypothesized that the amphiphilic nature of the 
copolymer contributes to form micelles. These micelles are formed by a PLGA 
(hydrophobic) core, and a PEG (hydrophilic) corona. As the temperature is increased, the 
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micelles associate to form the interconnected network that constitutes the gel. At sufficiently 
high temperatures, the hydrogen bonds are broken and the increased hydrophobicity of the 
polymer leads to a high degree of aggregation and to macroscopic phase-separation 81. 
Factors such as the molecular weight of the polymer, the length of the blocks, the 
composition of the hydrophobic block (ratio between lactic and glycolic acid), the polymer 
concentration and the presence of salts have been shown to influence the gel temperature, 
the critical gel concentration and the degradation rate of the hydrogel 78, 81. One important 
feature of the copolymers based on PEG and PLGA is that they are biodegradable and can 
last for a longer period of time 81. In addition, the release rate greatly depends on the nature 
of the drug. Particularly, it has been shown that hydrophobic drugs are released slowly and 
for longer periods of time, due to their preferential incorporation into the hydrophobic 
PLGA core 82. 
Some temperature-responsive polymers are characterized by having a lower critical solution 
temperature (LCST). The LCST can be defined as the critical temperature at which the 
polymer solution phase separates 68.  Below this temperature, the polymer chains are water-
soluble and form hydrogen bonds with the water molecules. However, as the temperature is 
raised above the LCST, the hydrogen bonds are broken and the hydrophobic associations 
dominate, causing the polymer in dilute solution to undergo coil-to-globule phase 
transitions, resulting in macroscopic phase-separation at higher polymer concentrations. In 
this process, the balance between the ratio of hydrophobic and hydrophilic monomers is of 
great importance 64, 75, 83. A figure illustrating the effect of LCST on the phase transitions of 
temperature-responsive polymers is shown in Figure 2. 
Figure 2. Effect of the lower critical solution temperature (LCST) on the phase separation behavior of 
thermoresponsive polymers. Below the LCST (left) the polymer chains (orange) are water soluble, due to 
hydrogen bonding with water molecules. Above the LCST (right) the hydrophobic associations dominate, the 
polymer aggregates and phase-separation takes place. Figure adapted from ref 83. 
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A number of review articles describe the wide variety of stimuli-responsive polymers that 
have been developed so far, including their structure, physicochemical properties and 
applications. The reading of the review articles by Ruel-Gariépy and Leroux 77, Gil and 
Hudson 68, Liu and Urban 67 and Talelli and Hennink 83 for instance, is suggested for more 
detailed information on this matter. 
In this thesis, however, most work involved the use of EHEC (in combination with ionic 
surfactants) and PNIPAAM block copolymers. Major emphasis will hence be given to these 
systems, as described in the following sections.   
1.3.1 Ethyl (hydroxyethyl) cellulose 
Ethyl(hydroxyethyl) cellulose (EHEC) is an amphiphilic nonionic cellulose derivative, 
widely used in the paint industry (where it forms protective colloids, acts as a thickening 
agent and helps to keep pigments in suspension) and in the building industries (where it is 
used as a dispersion agent in cement formulations) 84. EHEC is produced by chemical 
modification of cellulose, through the substitution of free hydroxyl groups with ethyl and 
hydroxyethyl groups (Figure 1). This substitution renders the polymer water-soluble 85. One 
of the most interesting properties of EHEC is its temperature-responsive behavior, caused 
by the presence of both hydrophobic and hydrophilic units, typically unevenly distributed 
along the polymer chains 86, 87. As the temperature is increased, EHEC becomes less water-
soluble, due to the enhanced hydrophobicity of the polymer (and less favorable interactions 
between the polymer and the solvent). As a consequence, EHEC solutions exhibit a phase 
separation behavior, as the LCST is reached. One of the phases is therefore enriched with 
the aggregated EHEC, and the other phase consists mainly of the aqueous solvent 88. 
The interactions between EHEC and ionic surfactants have been extensively studied over 
the years 86-93. In the presence of ionic surfactants, the phase behavior of EHEC solutions is 
significantly changed. The first consequence of the presence of ionic surfactants is that they 
arrange around the hydrophobic domains of the polymer, preventing the formation of large 
clusters as the temperature is increased. The arrangement of the ionic surfactants around 
these hydrophobic microdomains creates mixed polymer-surfactant micelles. At moderate 
surfactant concentrations, the connectivity of the system is increased. In addition, because 
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the surfactants are charged, the interaction with the polymer chains also endows these with 
an apparent polyelectrolyte character. In other words, the presence of moderate amounts of 
the ionic surfactant simultaneously contributes to an enhanced connectivity between EHEC 
chains, and causes the matrix to swell due to electrostatic repulsion. A temperature-induced 
viscosification is observed as the polymer becomes more hydrophobic with increasing 
temperature. The cloud point (CP) is also usually shifted to higher values, due to the 
improved thermodynamic conditions (increased solubility) created by the presence of the 
ionic surfactant. Depending on polymer concentration and polymer-to-surfactant ratio, a sol-
gel transition may occur at elevated temperatures 87, 88, 90, 94. At high surfactant 
concentrations, however, the connectivity of the system will be disrupted due the 
combinations of an excessive swelling effect and the solubilization of the hydrophobic 
domains by the surfactant molecules 86, 90. 
So far, most research on EHEC-ionic surfactant systems has been performed using 
conventional surfactants such as the anionic sodium dodecyl sulfate (SDS) 86-88, 90 and the 
cationic cetyltrimethylammonium bromide (CTAB) 86, 92, 93. However, the pharmaceutical 
use of such surfactants is limited due to their environmental toxicity, low chemical and 
biological biodegradability and poor biocompatibility 95.  
Only a few articles concerning pharmaceutical applications of EHEC-surfactant systems can 
thus be found in the literature. In one case, an EHEC-SDS gel system was developed for 
intranasal insulin administration  96. The formulation presented a low viscosity at room 
temperature, facilitating the administration to the nasal cavity, and formed a gel in situ as a 
consequence of the interactions between EHEC and the ionic surfactant. The viscous 
formulation was found to be mucoadhesive and to improve the nasal absorption of insulin 96. 
In another example, an in situ gelling formulation was developed from EHEC in 
combination with different surfactants for the delivery of lidocaine and prilocaine into the 
periodontal pocket (local anesthetic effect) 97. This study revealed that the presence of the 
drug can affect the polymer-surfactant interaction, even though under specific conditions the 
gelation behavior can still be retained 97. A gelling system combining EHEC and the ionic 
long chain alkyl betainate surfactant was also developed, using timolol maleate as the active 
ingredient for ophthalmic administration in the treatment of glaucoma 98. The phase 
behavior significantly depended on surfactant concentration, while the presence of the drug 
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generally shifted the gel region to higher surfactant concentrations. The gelling system 
allowed a slower release of the drug in comparison with the non-gelling formulation 98. 
Due to the complex interactions taking place between EHEC and the ionic surfactants, 
several parameters should be carefully considered in order to preserve the thermogelling 
capacity of the system and to produce a gel with the desired properties. 
Perhaps one of the most important factors to keep in mind is surfactant concentration, since 
low surfactant concentrations might be insufficient to cause charge repulsion, while high 
surfactant concentrations may cause excessive swelling and result in the disruption of the 
network 99, 100. A delicate balance between the hydrophobic associations and the 
electrostatic repulsion is therefore a pre-requisite to produce the temperature-responsive gel 
90, 100, as described by the model of Cabane et al. 94. 
Secondly, one should keep in mind that the gel point can in principle be tuned by changing 
the polymer concentration. For the EHEC/SDS and EHEC/CTAB system 93, it has in fact 
been shown that increasing the polymer concentration results in a decrease of the gel point. 
In consistency, increasing the polymer concentration also produces stronger gels. By using 
different surfactants with different charged head groups, the gel temperatures and the gel 
strength can also be altered 93. Karlström et al. 89 demonstrated that the phase behavior of 
semidilute EHEC solutions is affected by the length of the alkyl chains of the surfactant, the 
size and charge of the headgroup, and by the type of counterions present. 
It is also well-known that the interactions between EHEC and ionic surfactants are 
significantly affected by the salinity of the solution 100. In the presence of salts, it has been 
shown that higher surfactant concentrations are needed in order to increase the viscosity of 
the solution at high temperature, and that the cloud point decreases with increasing salt 
concentration 100. Different salt types can also have a different effect over the phase 
transitions of EHEC 101.  The effect of salinity on the rheological behavior of EHEC is 
explained by a screening effect of the charges of the ionic surfactants, which causes an 
increase of the connectivity of the system. In this context, higher surfactant concentrations 
are needed so as to restore the thermogelling capacity of the system 99, 100. This can be an 
important issue in parenteral formulations, since the presence of salts in the formulation is 
required to create isotonic conditions.  
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In drug delivery, it is finally important to emphasize that the presence of the drug itself can 
affect the rheological properties of the solution and the sol-gel transition 98, 101. For this 
reason, adjustments of the formulation components and concentrations may be required in 
order to produce an in situ gelling system optimized for the envisioned aim.  
1.3.2 Poly(N-isopropylacrylamide) 
One of the most extensively studied thermoresponsive polymers is poly(N-
isopropylacrylamide) (PNIPAAM) (Figure 1). This polymer can exhibit a phase transition at 
about 32 °C in water, depending on its concentration and molecular weight, and this 
proximity to human body temperature makes it particularly interesting for pharmaceutical 
and biomedical applications 102. PNIPAAM can additionally be copolymerized with other 
blocks in order to achieve combined properties, for instance in the case of the 
copolymerization of PNIPAAM with poly(acrylic acid) for both temperature- and pH-
responsiveness 103. The major limitation of PNIPAAM is its low biodegradability, but the 
copolymerization with other biodegradable polymers can partially help to overcome this 
issue 104. By copolymerization with other hydrophilic or hydrophobic blocks, one can also 
modify the LCST of the polymer, or produce distinct micellar structures for specific 
applications 105-107.  
Below the LCST of PNIPAAM, copolymers of PNIPAAM with hydrophobic segments can 
form core-shell micelles, where the core is composed of the hydrophobic domain and the 
shell is composed of the hydrated PNIPAAM. Hydrophobic drugs can therefore be 
incorporated in the core, while the hydrophilic shell contributes to stabilize the micelle and 
to increase the circulation time of the drug delivery system 104. As the temperature is 
increased above the LCST, the hydrophobic groups of PNIPAAM associate, causing the 
destabilization and aggregation of the micelles and triggering a fast drug release 104 (Figure 
3 a.). This reversible and thermo-sensitive response has been shown for adriamycin-loaded 
PNIPAAM-b-poly(butylmethacrylate) micelles, demonstrating the potential of these 
polymeric systems when used in combination with  localized hyperthermia 108. 
Another strategy is to conjugate or copolymerize PNIPAAM with a hydrophilic segment. In 
this case, PNIPAAM forms the core of the micelles (if the temperature is raised above its 
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LCST), while the hydrophilic domain is located at the surface, constituting the corona 
(Figure 3 b.). Another usual consequence of the presence of a permanently hydrophilic 
segment is the increase of the LCST of the thermo-responsive polymer 83, 104. One of the 
most well-studied hydrophilic polymers that have been copolymerized with PNIPAAM is 
polyethylene glycol (PEG). Below the LCST, PNIPAAM-b-PEG is highly hydrophilic and 
soluble in aqueous solution, while increasing the temperature above the LCST of the 
polymer causes the PNIPAAM block to aggregate due to its enhanced hydrophobicity. 
Micelles with a PNIPAAM core and a PEG shell are thereby formed 83, 104. In drug delivery 
technology, this has practical advantages, since a hydrophobic drug can be loaded by simply 
heating the solution to a temperature higher than the LCST of the polymer. In addition, the 
drug can be released from the micelles by local hypothermia, since the phase transitions are 
reversible 104, 109. 
Figure 3. Temperature-induced behavior of PNIPAAM-containing polymers. a. In the presence of a 
permanently hydrophobic segment, micelles are formed below the LCST of the polymer. Under these 
conditions, the hydrophobic polymer forms the core (black) and PNIPAAM (orange) forms the hydrated outer 
shell. The increase in temperature further causes the collapse of PNIPAAM and the destabilization of the 
micelles, which triggers the release of the drug. b. In the presence of a hydrophilic polymer segment (blue 
chains) and below the LCST, the polymer is water soluble. Above the LCST, micelles are formed. These 
micelles are formed by a PNIPAAM core (orange) and a hydrophilic polymer shell. Figure adapted from refs. 
108 and 83. 
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In gene delivery, PNIPAAM was first used in a block copolymer containing the positively 
charged PDMAEMA 110. In this case, the authors discussed that the presence of a positively 
charged polymer motivates the formation of electrostatic interactions with the negatively 
charged phosphate groups of DNA, thereby leading to the formation of polymer-DNA 
complexes. In addition, the copolymer was shown to be able to condense the DNA into 
small particles, while the overall presence of positive charges on the complexes was said to 
facilitate cell uptake, ultimately leading to higher transfection efficiencies 110.   
Other copolymers have been synthesized for the same purpose. Reports on the use of 
polyethyleneimine (PEI)-g-PNIPAAM 111,  trimethyl chitosan-g-PNIPAAM 112 and poly(L-
lysine)-g-PNIPAAM 113 can be found in the literature. 
PNIPAAM has also been widely formulated into hydrogels. This can be achieved e.g. by 
cross-linking with a chemical cross-linker such as N,N’-methylenebis(acrylamide) 114-116. 
Below the LCST, the hydrophilic amide groups of the polymer form hydrogen bonds with 
the surrounding water molecules and the network swells creating a gel. As the temperature 
is increased above the LCST, the hydrogen bonds are broken and the hydrophobic 
associations between the hydrophobic isopropyl groups increase, causing aggregation. In 
other words, the polymer becomes dehydrated, expelling a high amount of water, and 
collapses into a stiff and opaque structure 114, 115. This phase-transition behavior is 
reversible, and decreasing the temperature below the LCST will therefore result in the 
hydration and reswelling of the network 114, 115.  
It has been shown that the level of cross-linking of PNIPAAM gels can influence the 
porosity and release rates of loaded drugs 116. Furthermore, the properties of the hydrogels 
can be significantly changed by copolymerization of NIPAAM with other monomers. 
Copolymerization with a hydrophilic monomer, for instance, can induce the formation of a 
macroporous structure, due to the enhanced swelling and deswelling properties of the 
polymer 117. By changing the composition of the copolymer, one can also produce a system 
that undergoes physical gelation as a response to temperature changes. Self-gelling systems 
have been produced by synthesizing copolymers of PNIPAAM with hyaluronic acid 118 or 
alginate 119. The same strategy can be used to enhance the mechanical strength of the 
hydrogel and to prevent syneresis (expulsion of water from the gel), as shown for 
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PNIPAAM-g-methylcellulose 120. Comb-type structures also contribute to induce a fast 
transition (due to the high mobility of the temperature-responsive PNIPAAM grafted to the 
chain end), which is an essential feature in in situ gelling systems 118. 
For all the above mentioned, it is clear that PNIPAAM is a polymer of considerable interest.  
The phase changes that PNIPAAM undergoes as a response to temperature changes have 
motivated the scientific community to synthesize a wide range of PNIPAAM copolymers, 
having in mind specific applications, such as drug delivery, nonviral gene delivery, tissue 
engineering and cell culture 72, 78. The possibility to functionalize the polymeric carriers for 
a targeted delivery is also very attractive. This has been achieved e.g. by conjugation with 
biotin 121, 122 or folate 123, 124 for cancer therapy. 
1.4 Microparticles 
Microparticles (1-1000 μm 125, 126, typically smaller than 100 μm 127) are amongst the most 
well studied and established DDSs, due to their unique properties and advantages in the 
treatment of many diseases. Their large volume in comparison with nanocarriers allows the 
easy encapsulation of large amounts of drug, and the encapsulation of large molecules such 
as proteins and nucleic acids 126. In addition, these DDSs can show remarkable drug release 
properties, with long-standing effects being observed. Poly lactic-co-glycolic acid (PLGA) 
microspheres, for instance, have been developed for the sustained release of ȕ-metasone 
over a period of 11 days 128;  dexamethasone was released from PLGA particles for over a 
month 129, while in another study paclitaxel was slowly released from the microparticles for 
more than 110 days, when the DDS was formulated in the presence of appropriate 
emulsifiers or additives 130. 
Many methods have been employed to prepare microparticles, such as emulsification and 
solvent evaporation/extraction, phase separation (coacervation), spray-drying and in situ
polymerization 126, 131-133. The choice of the preparation method should be closely related 
with the properties of the polymer and drug, the intended site of action, and the intended 
duration of the therapy 131. 
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In 1986, Decapeptyl® by Ipsen became the first approved product of sustained-release 
injectable microspheres (gonadotropin-releasing hormone agonist). A number of other 
products are nowadays also in the market, to name a few Lupron Depot (leuprolide acetate, 
from Takeda), Risperdal Consta (risperidone, from Janssen) and Vivitrol (naltrexone, from 
Alkermes) 133. These products differ significantly in terms of particle size (up to 300 μm in 
some cases), polymer composition and molecular weight, and drug release properties 133. 
Typically, drug release from microparticles based on biodegradable polymers depends on 
diffusion, polymer erosion or a combination of both effects, and it is affected by the 
polymer and drug properties, particle porosity and size, drug loading and drug distribution, 
and presence of residual solvents 133, 134. The presence of enzymes and lipids can also have 
an important effect on the drug release rate in vivo 133. 
Drug release from microspheres is often described by a two-stage process. In the first stage, 
an initial burst of expelled drug is observed, due to excessive drug diffusion or drug 
desorption from the surface of the particles, whereas the second stage is defined by a more 
constant drug release rate, corresponding to both diffusion and polymer degradation effects 
134. A high burst release can cause toxic effects and decrease the amount of available drug in 
the system and should therefore be avoided 133. 
In this thesis, polymeric microspheres were developed as an additional barrier to drug 
release from a temperature-responsive hydrogel and with the intention of producing a 
controlled drug delivery system with a low initial burst release. This system can be 
compared with the production of PLGA microspheres loaded with transforming growth 
factor-ȕ1 (TGF- ȕ1) and embedded onto PEG-based hydrogels, as described by DeFail et al. 
135. 
1.5 Gene delivery 
In gene therapy, a vector containing nucleic acids is introduced into target cells so as to 
modify gene expression in a way that prevents, stops or reverses a pathology 136.  
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Viral vectors have shown to be the most efficient carriers for nucleic acids, particularly 
DNA. For this reason, scientists have developed genetically modified viruses by introducing 
foreign genes of interest, while deleting the genes that allow replication, assembling or 
infection of the virus 137, 138.  
In spite of their high efficiency, the use of viral vectors poses a number of concerns. In 
clinical trials, it has been shown for instance that the viral carriers can induce an excessive 
immune response due to the presence of viral capsid proteins, or lead to leukemia, due to 
random integration of the genes into the host chromosome 137. The production procedure is 
also quite complex, and the viruses are difficult to produce in a large-scale 137. 
Due to these disadvantages, nonviral gene delivery methods have been considered 
interesting alternatives to the viral carriers 137, 139. Nonviral carriers are generally recognized 
to induce low immune response and low toxicity, and they can be easily produced in large 
scale 137, 139. In addition, the nonviral carriers can be designed in order to target specific cells 
or tissues 139. The major limitation of the nonviral methods is that these are usually less 
efficient than the viral methods. In spite of this, the carriers can be administered repeatedly, 
if necessary, and the methods can be changed in order to improve the gene expression 139.  
The delivery of genes by nonviral carriers is a very challenging field that differs 
significantly from the DDSs described in the previous sections, used to systemically or 
locally deliver the active pharmaceutical ingredients. A number of requirements need to be 
fulfilled, and several barriers need to be surpassed until the therapeutic genes are integrated 
into the host’s genome. The DNA-carrier system must firstly overcome the extracellular 
barriers, such as the elimination by renal filtration and by the reticuloendothelial system 
(RES) in the liver, spleen and lung 137. In addition, the carrier should be able to protect the 
nucleic acids from the action of nucleases present in the blood and extracellular matrix. One 
critical step is crossing the plasma membrane; in this case, the carrier should further 
facilitate cell uptake, through mechanisms such as endocytosis, pinocytosis or phagocytosis 
137, 139. Once inside the cell, the system should escape the endosomes, in order to avoid 
enzymatic digestion, and finally it should travel to the nucleus where the transcription can 
take place after the carrier and the nucleic acid payload have been dissociated 139.  
In recent years, researchers have shown the potential of cationic polymers as nonviral gene 
carriers 35, 140, 141. Advantages such as the low immunogenicity, high structure versatility and 
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ease of production scale-up have been pointed out 140, 142. In addition, cationic polymers can 
condense DNA molecules to a smaller size as compared to cationic liposomes, which is an 
essential property for an efficient transfection 36. Review articles on the use of polymers 
(e.g. poly(L-lysine), PEI, poly(amidoamine) dendrimers, chitosan) as nonviral gene carriers 
can be found in the literature 36, 137, 139, 143, 144. Despite their advantages, the use of cationic 
polymers in gene therapy is still considered to be in its early stages 37. 
In this challenging field, stimuli-responsive polymers that transform their physicochemical 
properties in response to extra- and intracellular stimuli have received increasing attention 
145. Stimuli such as pH, redox potential, temperature and enzymatic activity have been 
shown to modulate the gene delivery ability of a polymeric carrier, while another possibility 
is to use artificial stimuli (e.g. light, ultrasound, magnetic field) to externally trigger the 
gene delivery pathways 145.  
Two of the most important requirements of a gene carrier is that it forms tight complexes 
with the DNA (protecting it from the degradation by nucleases, condensing it to an 
appropriate size and endowing it with a positive charge suitable for internalization) and that, 
once in the nucleus, it dissociates from the payload so that gene expression can take place 
146. The use of stimuli-responsive polymers is considered particularly advantageous in this 
context, since by applying a physical stimuli, such as light and temperature, complex 
association or dissociation can be controlled 146. In addition, by using stimuli-responsive 
carriers, one can control the site, timing and duration of the gene expression 146. 
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2 Aim of the project 
The major objectives of this project were to investigate different formulations based on 
temperature-responsive polymers in terms of their properties and applicability in drug and 
gene delivery.  
The specific objectives of this project can be described as follows. 
First of all, it was the aim of this work to develop a new injectable temperature-responsive 
hydrogel for drug delivery purposes. Such gel should be low toxic, exhibit low viscosity at 
(or below) room temperature and undergo gelation as the temperature is raised to 37 °C. In 
view of this purpose and having in mind the temperature-responsive properties of EHEC, 
the specific goals were: 
i. To study the rheological profile of EHEC in the presence of ionic amino acid-
based surfactants; 
ii. To explore the potential of this binary formulation as an in situ gelling system; 
iii. To investigate the cytotoxicity of the components of the formulation and to 
discuss the applicability of the system in drug delivery. 
Because it was hypothesized that the drug release capacity of the hydrogels could be 
improved through the combination of the gels with other controlled release systems, it was 
furthermore the aim of this work to develop polymer-based microparticles with enhanced 
stability properties. 
Another goal of this thesis was to investigate the potential use of temperature-sensitive 
polymers in gene delivery applications. In this case, the previous knowledge of the 
thermosensitive behavior of PNIPAAM allowed us to draw additional specific aims, 
including: 
iv. To study the efficiency of PNIPAAM block copolymers to interact and carry 
plasmid DNA into the nucleus of cells; 
v. To evaluate the effect of the polymer composition on the transfection efficiency; 
vi. To investigate the influence of the properties of the polymer-DNA complexes on 
the gene delivery potential. 
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3 Experimental considerations 
3.1 Materials 
The polymers and surfactants used in this work are indicated in sections below.  All other 
chemicals were of analytical grade and were used as received. Details on the materials used 
in each study can be found in papers I-V. 
3.1.1 Polymers 
A number of different polymers were used in this work. A summary of these polymers is 
given in Table 1, where some of the most important properties are also indicated. 
Ethyl(hydroxyethyl) cellulose (EHEC), mentioned in Papers I-III was gently offered by 
Akzo Nobel Surface Chemistry AB, Stenungsund, Sweden.  
In Paper IV, chitosan from crab shells was from Sigma (USA) and poly(lactic-co-glycolic 
acid) (PLGA) was from Aldrich (USA). The hydrophobically-modified chitosan (HM-
chitosan) was prepared according to a previously described procedure 147, 148, by reaction of 
the amino groups of the polymer chains with a C12 aldehyde.
In Paper V, four block copolymers based on poly(N- isopropylacrylamide)n-block-poly((3-
acrylamidopropyl)trimethylammonium chloride)m (PNIPAAMn-b-PAMPTMA(+)m) were 
studied. These block copolymers were distinct with respect to the length of the two blocks, 
where n = 48 or 65 and m = 6, 10 or 20. These polymers were synthesized by Dr. Kaizheng 
Zhu, Department of Chemistry, University of Oslo and the synthesis details can be found in 
the article by Bayati et al 149. 
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Table 1. Polymers used in this work. 
POLYMER SPECIFIC PROPERTIES MOLECULAR STRUCTURE PAPER 
NUMBER
EHEC Mn = 80,000 
DSethyl = 
1.9/anhydroglucose unit 
MSEO = 1.3/ 
anhydroglucose unit 
Mw/Mn = 2 
I, II, III 
Chitosan DD=75-85% 
MW = 300-500 kDa 
IV 
HM-chitosan DD=84% 
MW = 400,000 
C12-imine: 5 mol% 
(Chitosan: R= H or R= -CO-CH3
HM-chitosan: R= NH2 or R= NH-CO-CH3 or  
R= N=CH-C11H23) 
PLGA (RESOMER® RG 
502) 
Ester terminated 
Lactide:glycolyde 50:50 
MW = 7,000-17,000 
(x: number of lactic acid units, 
y: number of glycolic acid units) 
PNIPAAM48-b-
PAMPTMA(+)6
MW = 6,770 
Cloud point* = 35 °C 
(n:m= 48:6, 48:10, 48:20, 65:20) 
V PNIPAAM48-b-
PAMPTMA(+)10
MW = 7,600 
Cloud point* = 36 °C 
PNIPAAM48-b-
PAMPTMA(+)20
MW = 9,690 
Cloud point* = 37 °C 
PNIPAAM65-b-
PAMPTMA(+)20
MW = 11,600 
Cloud point* = 34 °C 
Mn – Number average molecular weight; DSethyl – Degree of substitution of ethyl groups; MSEO – Molar 
substitution of ethylene oxide groups; Mw/Mn – Polydispersity index; DD – Degree of deacetylation 
* determined for a polymer concentration of 0.3-0.7 wt%, depending on the maximum concentration used in 
the transfection experiments. 
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3.1.2 Surfactants 
A list of the surfactants used in papers I-III is shown in Table 2. All surfactants were amino 
acid-derived. It was expected that by using amino acid-based surfactants, low toxicity levels 
would be observed, rendering them suitable for pharmaceutical applications. 
In papers I and II, the following lysine-based surfactants were studied: sodium N,N’-
dihexanoyl-L-lysinate (6Lys6), sodium N,N’-dioctanoyl-L-lysinate (8Lys8) and sodium 
N,N’-didecanoyl-L-lysinate (10Lys10). These anionic double-chained surfactants were 
prepared by lysine acylation with natural saturated fatty acids as described elsewhere 150 and 
they were kindly supplied by Professor Eduardo F. Marques from the Department of 
Chemistry and Biochemistry, Faculty of Science, University of Porto, Porto, Portugal. 
In Paper III, three cationic arginine-based surfactants were investigated. Among these, one 
was a monomeric surfactant, and two had a gemini-like structure (bis(Arg) surfactants). The 
monomeric surfactant was NĮ lauroyl arginine methyl ester hydrochloride (LAM) and the 
gemini were of the type NĮ,Nω-bis(NĮ,-lauroyl arginine)Į,ω-alkylenediamides, having 6 or 9 
carbon atoms in the spacer (respectively designated C6(LA)2 or C9(LA)2). The synthesis 
procedure for these compounds can be found in previous publications 151, 152. The three 
arginine-based surfactants were generously supplied by Professor Aurora Pinazo, 
Department of Chemical and Surfactant Technology, IQAC-CSIC, Barcelona, Spain. 
ȱ ȱ ȱȱ
36
Table 2. Surfactants used in this work.
SURFACTANT SPECIFIC PROPERTIES MOLECULAR STRUCTURE PAPER 
NUMBER
6Lys6 
8Lys8 
10Lys10 
MW = 364 
cmc (25 °C)  200 mM 
MW = 420.5 
cmc (25 °C) = 7.0 mM 
MW = 475 
cmc (25 °C) = 0.29 mM 
(n=4, 6Lys6; n=6, 8Lys8; 
 n=8, 10Lys10) 
I, II 
LAM MW = 405.5 
cmc (25 °C) = 6 mM (ref 153)
III C6(LA)2
C9(LA)2
MW = 1057 
cmc = 2 x 10-3 mM (ref 153)
MW = 1099 
cmc = 3 x 10-3 mM (ref 153)
(n=6, C6(LA)2; n=9, C9(LA)2) 
MW –molecular weight; cmc – critical micelle concentration 
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3.2 Methods 
In this thesis, a variety of methods and techniques were used. Rheology was particularly 
relevant in papers I, III and IV, while cytotoxicity experiments were the focus of paper II 
and III. Cell viability studies were also employed in paper V. In paper IV, an emulsification-
solvent evaporation method was employed to produce polymeric microparticles, according 
to a planned experimental design. Finally, in paper V, gene delivery studies were carried 
out. The main points of these techniques and methods will be briefly described in the next 
lines. 
3.2.1 Rheology principles and Rheo-SALS 
In papers I and III, the interactions between EHEC and the amino acid-based surfactants 
were studied by the combined technique Rheo-Small Angle Light Scattering (Rheo-SALS). 
In Paper IV, the viscosity of chitosan and HM-chitosan was evaluated by rheology. The 
concepts on which these techniques are based will be briefly presented below. 
Rheology is concerned with the study of the deformation and flow of matter, when a 
mechanical stress is applied, and the studied parameters include the viscosity, elasticity, 
shear rate, shear strain and shear stress 154-157.  
Some simple substances such as water exhibit Newtonian flow features in the sense that the 
shear stress (σ) is proportional to the shear rate (ߛሶ) (where the constant of proportionality is 
the dynamic viscosity) at constant temperature and pressure.  
For most substances, however, this linear relationship does not apply. These complex fluids 
are called Non-Newtonian, and systems such as foams, emulsions, and polymer melts and 
solutions can usually be included in this group 154, 158. Some materials can for example 
demonstrate a decrease in viscosity at higher shear rates (shear-thinning or pseudoplastic 
behavior), or an increased viscosity at intermediate shear rates (shear-thickening or dilatant 
behavior)158. In some cases, the mechanical properties are intermediate between ordinary 
liquids and ordinary solids, and these fluids are hence designated as viscoelastic 154, 155. 
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Polymer solutions such as those studied in this thesis can exhibit strong viscoelastic effects, 
and/or shear thinning, shear thickening or time-dependent behavior 154.  
The complexity of these systems immediately suggests that they cannot be fully 
characterized by the viscosity values alone, but rather by a combination of parameters such 
as the frequency-dependent storage modulus (G’) and loss modulus (G’’) and the shear-rate 
dependency of the viscosity 154. For a complete characterization of the complex fluids, the 
relation of stress to strain must additionally be measured over a wide range of strains, strain 
rates and time scales 155. The ultimate aim is to relate the viscoelastic response with the 
material structures 155. 
In Paper V, the temperature-dependency of the viscosity of chitosan and HM-chitosan 
aqueous solutions was evaluated over a range of shear rates. In these steady shear 
measurements, a cone and plate geometry was used (Figure 4). The sample is placed 
between the stationary plate and the rotating cone. The cone angle is such that in each point 
on the cone surface, the ratio of angular speed and distance to the plate is constant. In other 
words, there is a constant shear rate across the entire radius of the cone.154 The system was 
equipped with a Peltier temperature control unit. 
Figure 4. Cone-plate geometry used to measure the viscosity of chitosan 
and HM-chitosan in Paper IV. Figure adapted from ref 156. 
In steady shear measurements using the cone-plate geometry, the shear rate ߛሶ  is related with 
the steady angular rotation speed of the cone Ω and with the cone angle Į (usually  0.10 
radians) according to the relationship:   ߛሶ ൌ :Ȁ ߙ 154. 
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After a steady shear flow is applied to the polymer solution for a suitable period of time, the 
shear stress (σ ) reaches a steady state. The determination of this value allows us to estimate 
the shear viscosity η  according to:   K ൌ VȀߛሶ 154. 
In papers I and III, a Rheo-SALS with a plate-plate geometry was used. The plate-plate 
geometry allowed measurements on a very low sample volume (0. 6 ml) due to the 
possibility to adjust the gap height. 
Temperature control was ensured by an external thermostat bath. The sample was applied 
between the two parallel plates, and the exposed surface of the sample was covered with a 
few drops of silicone oil, so as to prevent evaporation during the measurements. In this 
work, the rotating upper glass plate applied an oscillatory shear of small amplitude to the 
sample. Oscillatory shear experiments are widely used to characterize the viscoelastic 
behavior of non-Newtonian fluids. In polymer systems, oscillatory shear can also be used to 
monitor the viscoelastic properties of the networks during gel evolution 159. 
In these experiments, the material is subjected to a sinusoidal deformation and the resulting 
mechanical response is measured over time 160. The viscoelastic response of a sample such 
as a polymer solution is quantified by the elastic storage modulus (G’) and the viscous loss 
modulus (G’’) 160. In this work, G’ and G’’ were estimated over a range of angular 
frequencies (ω).  
In Paper I and III, the acquired rheological data was further used to assess the gel points. 
According to the method of Winter and Chambon 161, the gel points can be determined by 
the determination of the frequency-independent value of the viscoelastic loss tangent or 
damping tan δ (where δ is the phase angle between stress and strain and tan δ = G’’/G’). In 
other words, the gel point can be determined by plotting tan δ versus temperature at 
different frequencies. The intersection point of the curves indicates the gel point. 
The gel point can also be found by plotting the apparent viscoelastic exponents n’ and n’’
(G’ ~ ωn’; G’’ ~ ωn’’) at different temperatures, and finding the crossover where n’ = n’’ = n.
When a gelling system is identified, the structure of the network can be defined by the gel 
strength parameter (S). This parameter is determined by the equation 
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( ) įcosn1īnSȦįtan 
G
G −=
′′
=′ , where S is the gel strength parameter and Γ(1-n) is the Legendre 
gamma function. The gel strength depends on factors such as the molecular weight of the 
polymer and the cross-linking density and molecular chain flexibility 159, 162. 
Finally, the rheological data was also used to determine the fractal dimension (df), indicative 
of the homogeneity of the network, according to the model of Muthukumar 163 and the 
equation: ( )( )f
f
d-2d2
2d-2dd
n
+
+
= , where d represents the space dimension (d=3).
While the rheological methods reveal important information concerning the rheological 
behavior of soft materials and their macroscopic properties, it is often desirable to acquire 
information related with the underlying microstructures 155, 164. This can be achieved by 
combining standard rheometers to optical systems, e.g. via fluorescence microscopy or 
magnetic resonance imaging, or via scattering techniques such as SALS 155, 164. In SALS, a 
laser beam is applied to the sample, 2D scattering patterns are acquired and the angular 
distribution (and intensity) of the scattered light is measured164. Specific orientations and 
deformations of a material can for instance be identified by a stretched scattering pattern 164, 
while the occurrence of aggregates can result in an augmented intensity and/or radius of the 
2D pattern 165.  
A picture of the combined Rheo-SALS instrument used in this work is shown in Figure 5. 
Simultaneously with the application of an oscillatory shear, a primary laser beam was 
focused on the sample. The scattered light was collected by a lens system and the 2D 
scattering patterns were transferred onto the CCD chip of a camera. 
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Figure 5. Rheo-SALS instrument used in this study (plate-plate 
geometry), showing the rotating upper plate and the laser beam (inset). 
By analyzing the intensity of the scattered light, one can also determine the cloud points, 
taken as the temperature at which a very sharp intensity increase is observed.  
3.2.2 Cell viability studies 
In papers II and III, cell viability studies were carried out in order to investigate the 
cytotoxicity of the amino acid-based surfactants and the corresponding surfactant-EHEC 
gelling systems.  
All cell viability studies were carried out in human HeLa cells (epithelial cervical carcinoma 
cell line).  
Cells were incubated with the surfactants at different surfactant concentrations or with the 
gelling systems for a period of 24 h at 37 °C. After this time, cell viability was estimated by 
the modified Alamar Blue or resazurin assay. In this method, the dark blue resazurin 
(Sigma-Aldrich, USA) is reduced to the pink and highly fluorescent resorufin in the 
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presence of living cells 166 (Figure 6). By colorimetry, it is therefore possible to investigate 
the oxido-reductive capacity of the cells, which reflects the cell viability and proliferation. 
One important advantage of Alamar Blue in relation to 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide (MTT), the most conventionally used compound in toxicity 
assessment, is the fact that Alamar Blue is nontoxic, not causing cell death during the 
measurements, and allowing cell reuse 166. Positive (untreated cells) and negative (absence 
of cells) controls were prepared in all experiments. 
The cell viability was calculated according to the equation: 
100
cellscontrolof)A(A
cellstreatedof)A(A
(%)viabilityCell
600570
600570 ×
−
−
=
In Paper V, similar viability studies were carried out in parallel with the gene delivery 
experiments. In this case, however, cell viability was measured 44 h after the initial 
transfection period (4 h), in agreement with the transfection protocol used. 
The complete procedure concerning the viability studies can be found in Papers II, III and 
V.  
Figure 6. a. Reduction reaction of Alamar Blue (resazurin) in viable cells due to the presence of 
reducing metabolites; b. color modification observed in 98-well plates such as those used in this 
project (pink showing the presence of resorufin and indicating the presence of viable cells, and dark 
blue showing cells with low reducing capacity, interpreted as low viability wells). 
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3.2.3 Production and characterization of microparticles for drug delivery 
In Paper IV, polymer-based microparticles were formed as carriers for a model drug 
(naltrexone). The microparticles were produced by an emulsification-solvent evaporation 
method. In the single emulsion strategy, the polymer and drug are firstly dissolved in an 
appropriate solvent and dispersed in a continuous immiscible phase by stirring in the 
presence of an emulsifier. Droplets are thereby formed and transformed into hard spheres as 
a consequence of the evaporation of the solvent 131, 133. Finally, the microparticles can be 
recuperated, washed and dried or freeze-dried 133.  
In the case of water-soluble drugs, it is sometimes advantageous to prepare a double 
emulsion, i.e. by dispersing the aqueous polymer + drug solution in an organic solvent 
(water-in-oil emulsion) and adding this primary emulsion to an aqueous phase containing an 
emulsifier, hence forming a water-in-oil-in-water (w/o/w) emulsion 132. In this work, 
however, the model drug (naltrexone) was not significantly water-soluble and the 
production of a double emulsion was considered unnecessary. 
The emulsification-solvent evaporation method is one of the most widely used methods to 
prepare microparticles, and it has important advantages such as the simplicity and 
inexpensiveness of the procedure and instruments, and the fact that it allows the control of 
process parameters 133.  
Taking advantage of the possibility to control these parameters, an experimental design was 
developed, in order to investigate the influence of factors such as polymer concentration, 
needle diameter (used to add the polymer solution to the continuous phase), stirring speed 
and temperature (in the emulsification stage), on the microparticles’ size properties (in the 
absence of drug). The procedure according to the emulsification-solvent evaporation method 
is outlined in Figure 7. 
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Figure 7. Emulsification-solvent evaporation method used for the production of chitosan and HM-chitosan 
microparticles. The numbers in the orange boxes represent the factors investigated in the experimental design, 
i.e. polymer concentration (1), needle diameter (2), stirring speed (3) and temperature (4).  
* In the case of PLGA microparticles, the polymer was dissolved in dichloromethane, the emulsification of the 
polymer solution was carried out in water containing polyvinyl alcohol as the emulsifier, and water was added 
in the solvent extraction step.  
In general, statistically designing the experiments and making several factors vary 
simultaneously has several advantages over the strategy of varying one factor at a time. A 
designed experiment requires fewer resources (time, material, etc.) and offers the possibility 
to estimate individual effects and the interaction between factors, and the response curvature 
in the experimental region (response deviation from linearity). In addition, the experiments 
are planned in advance and the developed model can give a good prediction of the response 
over the entire factor space 167, 168. 
In this work, we planned to analyze the effect of 4 factors (indicated by the numbers in the 
orange boxes, Figure 7) on the size and size distribution of the polymeric microparticles. A 
full factor experimental design with two levels (high and low) would imply 24 = 16 
experiments plus 3 center points (analysis of the experimental curvature and analytical 
variability). Considering that 3 polymers (chitosan, HM-chitosan and PLGA) were used as 
the polymeric matrix, a full experimental design would involve a minimum of 48 
experiments in addition to the center points. The large number of experiments was therefore 
the reason for designing a fractional factorial design, corresponding to 24-1 = 8 experiments 
(plus 3 center points) for each polymer (total of 33 experiments). By doing so, the main 
effects and interactions can still be determined, but this implies that the two-factor 
interactions cannot be distinguished from each other (confounding effect) 168.  
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After the determination of the effects of the process parameters, specific conditions were 
used to prepare naltrexone (NTX)-loaded microparticles based on the three polymers. 
Details of the emulsification conditions can be found in Paper IV. The microparticles were 
further analyzed in terms of production yield, drug content, morphological features and 
controlled release capacity, as described in the paper. 
3.2.4 Production and characterization of polyplexes, and gene delivery studies  
In Paper V, the thermoresponsive PNIPAAM-b-PAMPTMA(+) block copolymers were 
evaluated as gene carriers in HeLa cells. 
Polyplexes were formed by incubating the polymer solutions with plasmid DNA coding for 
green fluorescent protein (GFP) for 20 min, at pre-defined polymer nitrogen-to-DNA 
phosphate (N/P, +/-) charge ratios. The cells were incubated with the polyplexes at 37 °C 
for 4h, the medium containing the polyplexes was then replaced with fresh medium and the 
cells were incubated for another 48h to allow gene expression. In the end, cells were 
detached from the plate wells and the fluorescence was measured by flow cytometry. In this 
instrument, physical and chemical features of cells are evaluated as the cells are made to 
flow through the instrument in a fluid stream. A laser light is focused onto the flow cell by a 
focusing lens. As the laser light passes through the cells, the light is scattered, filtered and 
directed to the photodetectors that convert the light into electric signals. Forward scatter 
detectors placed in line with the light beam provide a suitable detection of particles that are 
larger (such as masses consisting in two or more cells) or smaller (such as cell debris) than 
the normal cell size, while side scatter detectors, placed at approximately 90 degrees from 
the laser path, measure the side-scattered light that is proportional to cell granularity or cell 
internal complexity. If the cells contain fluorochromes such as GFP, these will be excited 
and emit fluorescence, which is then collected by fluorescence detectors. The scattered data 
is ‘gated’ i.e. a subset of measurements is created, so as to include the intended particle 
characteristics only in further analysis (dead cells, other cell types and debris can be 
excluded in this way) (information provided by the manufacturer, BD Biosciences, USA). 
The transfection efficiency (based on GFP fluorescence) was calculated with basis on the 
scattered data of the sample in relation to the untreated (control) cells.  
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The properties of the polyplexes prepared at specific N/P ratios were analyzed in terms of 
DNA protection ability, zeta potential, size and turbidity (in aqueous buffer). The detailed 
procedures concerning the transfection experiments and the characterization of the 
polyplexes are given in Paper V.  
3.2.5 Other experimental techniques 
In addition to the methods described above, a number of other techniques were used to 
characterize the systems under investigation. Specifically, in paper IV, the size and size 
distribution of the microparticles was evaluated by using a particle sizing instrument that 
measures particle size by detection of the magnitude of the obscured light, in dilute 
suspensions (detecting one particle at a time). The controlled release properties of the 
microparticles were investigated by an in vitro method. The released drug was quantified by 
measuring its absorbance at a specific wavelength, in a spectrophotometer, and with 
resource to a calibration curve. 
In paper V, dynamic light scattering was used to determine the hydrodynamic radius (Rh) of 
the polyplexes. Zeta potential measurements were employed to characterize the electrostatic 
potential near the surface of the surfactant micelles (paper I) or the polyplexes (paper V). 
Turbidity measurements were carried out by measuring the transmittance of aqueous 
suspensions of the polyplexes (paper V), in order to investigate their structural 
arrangements, e.g. compactness, in suspension. Details of the procedure are given in the 
relevant papers. 
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The papers included in this thesis reflect the steps taken towards the development of new 
thermoresponsive gel systems for the delivery of conventional drugs, and with potential in 
gene delivery applications, as summarized in the following chart.  
Scheme 1. Outline of this thesis based on the investigated subjects and published papers. 
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4.1 Paper I 
EHEC is a well-known amphiphilic polymer, and at sufficiently high concentrations 
(semidilute regime) it is able to form temperature-dependent hydrogels in the presence of 
ionic surfactants. In the first paper, the interactions between EHEC and three ionic 
surfactants were explored. The ionic surfactants investigated here had a gemini-like 
structure and lysine as the polar head group. The surfactants were distinct in terms of the 
length of the alkyl chains, comprising 6, 8 or 10 carbon atoms (respectively designated 
6Lys6, 8Lys8 and 10Lys10). It was therefore hypothesized that these surfactants could 
replace the conventional and more toxic surfactants such as SDS and CTAB in the induction 
of sol-gel transitions of EHEC solutions. Rheological measurements were carried out by 
Rheo-Small Angle Light Scattering. The solutions showed a low viscosity in the presence of 
all surfactants at low temperatures. In addition, the viscosity tended to increase with 
temperature, in manner that greatly depended on the surfactant type and its concentration. 
Sol-gel transitions were observed at specific surfactant concentrations (lower for the longer 
chain-length surfactants) as the temperature was increased. At this point, the associations 
between the hydrophobic groups of EHEC are balanced by the swelling caused by charge 
repulsion, inducing gelation. Due to the higher association tendency of the longer chain-
length surfactants, these were able to form gels at lower concentrations, but in this case the 
gel point was found to shift slightly to higher values. In the presence of all surfactants, soft, 
homogeneous gels were produced, as determined by the estimation of the gel strength 
parameter and fractal dimension values. Finally, the 2D SALS patterns allowed the 
estimation of the cloud points and provided further evidence of the association tendencies of 
the systems. 
4.2 Paper II 
The premise of the previous paper was that the amino acid-based surfactants could be more 
biocompatible than the conventional surfactants, which would open a window towards their 
potential use (and of the hydrogels produced by their combination with EHEC) in 
pharmaceutical and biomedical applications.  
In Paper II, the toxicological properties of the lysine-based surfactants and of the EHEC-
surfactant hydrogels were investigated, by using in vitro experiments on a human cell line 
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(HeLa cells). The EC50 of the surfactants, i.e. the concentration that induces a response 
halfway between the baseline and the maximum response, was found to decrease with the 
increasing chain length, suggesting a higher toxicity for the most hydrophobic surfactant. 
Importantly, the most hydrophilic surfactant (lower chain-length) was less toxic than the 
commercial SDS and CTAB. Having in mind the aforementioned potential applications of 
the surfactants, it was deemed important to evaluate the toxicity with respect to the 
‘effective concentration’, i.e. the concentration previously shown to induce gelation of 
semidilute solutions of EHEC. In this context, the longer chain-length surfactant was found 
potentially interesting, since its higher toxicity is partly compensated by its high efficacy 
(implying the use of very low concentrations for the intended result).  
In the final part of this paper, the cytotoxicity of the EHEC-surfactant hydrogels was 
evaluated. The results showed that the polymer contributes to cell stabilization and to a 
decrease of the toxicity caused by the presence of the ionic surfactant. The conjecture was 
that the presence of EHEC causes the surfactant molecules to preferentially interact with the 
polymer’s hydrophobic groups, leaving the surfactant molecules less available to adsorb and 
disrupt the cell membranes.  
Considering the applications for human use, this work showed that hydrogels comprising 
lower chain-length surfactants are less likely to cause cytotoxic effects, while the longest 
chain-length counterparts can also constitute promising alternatives, considering their high 
efficiency at low concentrations.  
4.3 Paper III 
This paper described the studies on an alternative system comprising EHEC and arginine-
derived surfactants. One monomeric surfactant, NĮ-lauroyl-L-arginine methyl ester (LAM) 
and two gemini surfactants with distinct spacer length (6 and 9 carbon atoms, respectively 
designated C6(LA)2 and C9(LA)2) were analyzed and compared in terms of the rheological 
properties in the presence of semidilute EHEC solutions. The complex viscosity was 
generally low at low temperatures and progressively increased as the temperature was raised 
and as the associations within and between polymer chains increase. It was noticeable that 
the concentrations at which sol-gel transitions were observed were significantly higher for 
LAM than for the more efficient gemini surfactants. The gel point, fractal dimension and gel 
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strength were all found dependent on the type and concentration of surfactant. Rheo-SALS 
also revealed that in the presence of very high concentrations of the gemini surfactants (ca. 
1000 times the critical micelle concentration), a second viscosification peak is observed, 
which is probably related with the self-assembling properties of the surfactants in the bulk, 
rather than an effect of the interactions with the polymer. 
The scattered intensities of the incident light on the samples (measured by SALS) were used 
to determine the cloud point values. A pronounced effect of surfactant concentration was 
observed when LAM was used. Conversely, changing the concentration of the gemini 
surfactants only had a minor effect on the cloud point. 
This paper also describes the results of in vitro cytotoxicity experiments carried out on a 
human epithelial cervical carcinoma cell line. The monomeric surfactant was shown less 
toxic than the gemini counterparts, in consistency with its lower hydrophobicity created by 
the presence of a single alkyl chain. An interesting finding was also that C6(LA)2 was shown 
to be more toxic than C9(LA)2, in spite of the longer spacer present in the latter. This 
observation was related to the increased flexibility of longer spacers, a feature that can 
change the conformation of the molecules in the aqueous environment and affect their 
interaction with the cells. In the presence of the hydrogels, i.e. at the surfactant 
concentrations previously shown to induce sol-gel transitions of semidilute EHEC solutions, 
cell viability was found significantly higher in the presence of the gemini surfactants than in 
the presence of LAM. This was related to the higher gel-forming efficiency of the gemini 
surfactants compared to LAM, for which very high concentrations are necessary in order to 
induce gelation of EHEC at high temperatures. 
4.4 Paper IV 
Paper IV describes the study of polymer-based microparticulate systems for the delivery of 
a low water solubility drug – naltrexone (NTX).  
Having in mind the use of the prepared hydrogels (Paper I, II and III) as sustained drug 
release systems, it was envisioned that the drug release rate could be improved by 
combining the hydrogels with drug-loaded microparticles. In other words, the two-
component system would involve: 
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i. drug-loaded microparticles 
ii. a temperature-responsive polymer solution, serving as a suspension medium for 
the microparticles. 
The injection of this system should allow the in vivo gelation of the solution (due to the 
temperature increase), forming a depot system that, while restricting the movement of the 
microparticles, could allow the slow diffusion of the drug, and result in a long-standing 
therapeutic effect. A scheme describing this principle is shown in Figure 13. 
In Paper IV, the first step into the development of this depot system is given, by exploring 
the production of NTX-loaded microparticles in the absence of the hydrogel and by 
investigating their controlled release properties. 
A hydrophobically-modified (HM) chitosan (containing C12 groups) was used to prepare the 
microparticles, since it was expected that the chemical modification would improve the 
long-term stability of the polymer. For comparison, microparticles were also prepared from 
an unmodified chitosan and from the hydrophobic poly lactic-co-glycolic acid (PLGA). All 
samples were prepared using an emulsification-solvent evaporation method.  
HM-chitosan microparticles showed the highest yield and drug encapsulation efficiency 
(EE), which was related with the high viscosity of the HM-chitosan polymer solutions and 
with the strong interactions between the polymer and NTX. Furthermore, this study showed 
that high HM-chitosan concentrations and rapid solvent evaporation rates contributed to 
increase the drug loading, while this also caused the particles to become larger. Excluding 
the cases where high concentrations of HM-chitosan were used, most microparticles were 
smaller than 50 μm. Drug encapsulation within chitosan and PLGA microparticles was 
generally less efficient, possibly due to the lower viscosity of the dispersed phase and due to 
weaker polymer-polymer interactions and fewer polymer-drug associations.  
In this article, the in vitro release rate of NTX was also evaluated, and showed that, in spite 
of a moderate initial burst release, HM-chitosan microparticles were more able to control 
drug release than PLGA or chitosan microparticles, in the long-term. A slow drug release 
rate was observed for at least 50 days. It was assumed that the hydrophobic groups 
functioned as physical cross-linkers of the matrix, due to the establishment of hydrophobic 
inter-chain associations. It is also likely that NTX, being a low water solubility drug, has a 
high affinity to this polymer, which explains the high EE and the low drug release rates.  
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This study revealed the potential of hydrophobically-modified polymers in long-standing 
drug delivery applications.  
4.5 Paper V 
In paper V, the physicochemical characterization of PNIPAAM-based temperature-
responsive polymers is described, when these were combined with DNA for gene delivery 
purposes. 
The results shown in this paper derived from the cooperation with the Center for 
Neuroscience and Cell Biology (Molecular Biotechnology and Health – Vectors and Gene 
Therapy, University of Coimbra, Portugal), specialized in gene delivery studies. In this 
work, four temperature-responsive polymers, synthesized in our group, were evaluated in 
terms of their potential to form complexes (polyplexes) with plasmid DNA (pDNA, coding 
for green fluorescent protein or GFP) and deliver it efficiently to the nucleus of HeLa cells. 
The polymers consisted of two blocks, one of which comprising the temperature-responsive 
PNIPAAM and the other a positively charged PAMPTMA. The four block copolymers were 
additionally distinct in terms of the length of each block.  
When incubated with the cells, the polyplexes were shown to efficiently deliver the pDNA 
into the nucleus, where the expression of GFP was monitored by a flow cytometer. The 
extent of gene expression and associated toxicity varied expressively among the four 
polymers, and these results were also found dependent on the charge ratio between polymer 
and DNA (N/P or +/-). All polymers were shown to protect DNA in an effective manner. 
Polymers containing a long PNIPAAM block and having a short charged block were found 
to be more efficient gene carriers. Higher concentrations also contributed to higher 
transfection efficiency, but caused greater toxic effects. 
The differences observed between the systems were further investigated by studying the 
physicochemical properties of the polyplexes, namely size, zeta potential and turbidity, and 
at the temperatures used in the transfection experiment. The determination of these 
properties provided some insight into the relationship between polymer composition and the 
resulting polyplex structures.  Ultimately, this study also revealed some important 
information regarding the influence of the structures of the temperature-responsive 
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polyplexes over their gene delivery efficiency. The key point was that the use of positively 
charged polymers as gene carriers allows a strong interaction with the oppositely charged 
DNA, while the thermoresponsive behavior contributes to encapsulate the payload at 
physiological temperature. 
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5 Results and Discussion 
5.1 Thermoresponsive hydrogels as DDSs 
In this thesis, the first objectives were related with the development of a thermoresponsive 
gel system demonstrating low viscosity at low temperatures and gelation at higher 
temperatures. This system was intended as a drug delivery formulation that can be easily 
injected due to the low viscosity at low temperatures, forming a gel in situ as a response to 
body temperature.  
In view of these objectives, the EHEC-ionic surfactant system was investigated, using the 
lysine- and arginine- based surfactants indicated in Table 2 (page 36). The rheological 
properties of the systems were evaluated (Papers I and III), while their in vitro toxicity was 
also investigated on a human cell line (Papers II and III), due to the envisioned 
pharmaceutical use.  
By using ionic amino acid-derived surfactants, it was anticipated that the toxicity of the 
system would be decreased as compared to the use of conventional surfactants. This 
principle has actually been claimed previously 169-172. 
In this work, a total of 6 surfactants were investigated as components of semidilute aqueous 
EHEC solutions (polymer concentration= 2 wt%). The use of semidilute polymer solutions 
was deemed very important, since in this regime the polymer chains overlap, thus ensuring 
the connectivity of the network under the appropriate conditions. Of all surfactants, three 
were anionic and synthesized from lysine (Papers I and II), and contained two C6, C8 or C10
alkyl chains, hence being designated 6Lys6, 8Lys8 and 10Lys10. These double-chained 
surfactants contained two polar heads covalently linked to each other by a short alkyl chain 
of constant length (spacer). By analyzing the three lysine-based surfactants, it was therefore 
possible to evaluate the effect of the alkyl chain length on the rheological properties of 
EHEC semidilute solutions.  
In contrast with the former, the arginine-based surfactants were cationic. Two of these also 
had a gemini-like structure, but in this case they differed in the spacer length, i.e. C6(LA)2 
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containing a C6 spacer, and C9(LA)2 containing a C9 spacer. The importance of the spacer 
length could consequently be probed in terms of the gel-forming properties of EHEC 
solutions. In addition, these gemini-like surfactants were compared with the corresponding 
monomeric LAM.  
Figure 8 shows the effect of temperature and surfactant concentration on the viscosity of 
EHEC solutions. All systems demonstrated low viscosities at room temperature, and higher 
viscosities at 37 °C, depending on surfactant concentration.  
Figure 8. Complex viscosity of EHEC-surfactant systems at 25 and 37 °C, at different surfactant 
concentrations. EHEC concentration = 2 wt% in all systems.
When small amounts of the amphiphilic surfactant molecules are present, they assemble in 
the vicinity of the hydrophobic groups (Figure 9 b.). In addition, one of the most striking 
properties of mixed polymer-ionic surfactant systems is the fact that the formation of mixed 
micelles at moderately high surfactant concentrations causes a viscosification of the 
solution, as shown in Figure 8 for all systems at 37 °C. The underlying reasons are twofold, 
since the mixed micelles act as cross-linking points (connecting two or more polymer 
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chains) and cause the matrix to swell due to charge repulsion between the ionic surfactant 
molecules. It is the balance between these effects (Figure 9 c.) that causes the viscosification 
of the polymer solution, and allows the sol-gel transition at adequate surfactant 
concentrations. This behavior between amphiphilic polymers and ionic surfactants has been 
extensively discussed before 87, 88, 90, 94.  
Figure 9. Effect of surfactant concentration on the network structures. a. Absence of surfactant; b. In the 
presence of small amounts of surfactant, the surfactant molecules arrange around the hydrophobic 
microdomains of the polymer; c. At sufficiently high surfactant concentrations, the widespread formation of 
mixed polymer-surfactant micelles increases the connectivity of the network (the connectivity is balanced by 
the charge repulsion effect of the ionic surfactant); d. At high surfactant concentrations, the connectivity of the 
system will be disrupted due the combinations of an excessive swelling effect and the solubilization of the 
hydrophobic microdomains by the surfactant molecules.
In general, the results in Figure 8 show that the surfactant concentration at which the 
increase in viscosity is observed follows the cmc trend, i.e. occurring at lower 
concentrations for the surfactants with lower cmc (values shown in Table 2, page 36). In the 
case of the Lys-based surfactants, the increase in alkyl chain length causes an increase in the 
hydrophobicity of the surfactant that tends to associate at lower concentrations. In the 
presence of the amphiphilic EHEC, this implies a decrease in the critical aggregation 
concentration (cac) and a decrease in the surfactant concentration that leads to the viscosity 
increase at elevated temperatures. Accordingly, the remarkably low cmc of the gemini 
arginine-based surfactants (2 x 10-3 mM for C6(LA)2 and 3 x 10
-3 mM for C9(LA)2, Table 2) 
causes them to associate at very low concentrations. This has major implications from a 
prospective industrial use, since very low amounts are needed in order to cause 
viscosification of the EHEC solution (surfactant concentration in the range 1 x 10-3 to 1 x 
10-2 mM). In addition, the need for lower surfactant concentrations is expected to contribute 
to a lower toxicity, as will be discussed later. In contrast, the lower efficiency and higher 
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cmc of the monomeric surfactant LAM causes it to associate (and increase the viscosity) at 
significantly higher concentrations, as shown in Figure 8. 
In all cases, the viscosity tends to decrease as the surfactant concentration is further 
increased. At this stage, the connectivity of the system will be disrupted due the 
combinations of an excessive swelling effect (due to charge repulsion) and the solubilization 
of the hydrophobic domains by the excess of surfactant molecules 86, 90. This scenario is 
illustrated in Figure 9 d.
In Paper III, it was also discussed that C9(LA)2 probably forms self-associating structures at 
very high concentrations (ca. 1000 times higher than the cmc), as a consequence of strong 
hydrogen bonding within and between the surfactant molecules and the surrounding water. 
This behavior was suggested as the reason for the observed second viscosity maximum. 
The sol-gel transitions were determined as described before in the section ‘Experimental 
considerations’. Pictures of some gels (no flow observed as the temperature is increased and 
the vial is inverted) are shown in Figure 10. The most significant gel points and gel 
parameters are also indicated in Table 3. 
Figure 10. Examples of 2 wt% EHEC in the presence of the surfactants at 25 °C (a.) and at 37 °C (b.-d.).  
a. and b. – 5 mmolal 6Lys6; c. – 2 x 10-3 mmolal C6(LA)2; d. – 1 x 10-3 mmolal C9(LA)2. 
The surfactant concentration inducing a sol-gel transition in semidilute EHEC solutions was 
found to vary among the different surfactants, essentially following the previously discussed 
relationship between cmc and concentration at which the viscosity increase is observed. The 
most effective surfactants were the arginine-based surfactants with a gemini-like structure. 
These surfactants aggregate at low concentrations (low cac) due to the presence of the long 
alkyl chains and spacer (structures shown in Table 2). In contrast, the highest surfactant 
concentrations inducing gelation of EHEC were found in the case of LAM, the only 
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monomeric surfactant analyzed, which clearly demonstrates the lower surface activity and 
efficiency of the monomeric surfactants with respect to the dimeric or gemini counterparts.  
The gel points were found between 36 and 44 °C. The fact that in most cases the fractal 
dimension (df) was 2.4 suggests the formation of relatively homogeneous, closed networks 
87, 93. However, the fact that the gel strength was not higher than 19 Pa.sn indicates the 
presence of soft gels which are weaker than those reported before in the presence of CTAB 
(S = 25 Pa.sn) and SDS (S = 45 Pa.sn) 93. Nonetheless, it is likely that stronger gels are 
produced using higher polymer concentrations, as shown previously for the EHEC/SDS and 
EHEC/CTAB systems 93. 
When gels were formed at different concentrations of the same surfactant (i.e. for C6(LA)2 
and C9(LA)2), an increase in surfactant concentration generally caused the gel point to 
increase and the gel strength parameter to decrease. This is caused by the excess of 
surfactant which leads to a higher solubilization of the polymer’s hydrophobic 
microdomains. As a result, a higher temperature is necessary to create the connectivity 
necessary to cause the sol-gel transition, and the resulting gels still demonstrate a weakened 
network (lower S values). 
Table 3. Gel properties of the thermoresponsive EHEC-surfactant systems investigated in this work.
SURFACTANT SURFACTANT 
CONCENTRATION 
(mmolal)
GEL POINT
(°C)
GEL STRENGTH 
PARAMETER 
(S, Pa.sn)
FRACTAL 
DIMENSION
(df)
6Lys6 5.0 37.0 14.2 2.4 
8Lys8 3.0 39.0 17.2 2.4 
10Lys10 0.1 40.0 17.5 2.4 
C6(LA)2
2.0 x 10-3 36.5 18.3 2.4 
1.0 x 10-2 40.0 17.1 2.4 
1.5 x 10-2 44.0 14.3 2.4 
C9(LA)2
2.0 x 10-3 39.0 18.9 2.5 
1.0 x 10-2 43.0 16.4 2.4 
3.0 x 10-2 39.0 5.6 2.4 
LAM 12.0 36.0 14.2 2.1 
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In papers I and III, the polymer-surfactant systems are also characterized in terms of the 
cloud point profile at different surfactant concentrations (Figure 11). The CP is defined by 
the temperature at which the polymer solution undergoes a microscopic phase separation 
and this is shown by a turbidity increase as this temperature is reached 173, 174.  
Figure 11. Effect of surfactant type and concentration on the cloud point values of the EHEC-surfactant 
system. The arrows in the figure indicate an increase in the cloud point to values higher than the instrument’s 
upper temperature limit (44 °C). The gel points at specific surfactant concentrations are also indicated by the 
star symbols in the figure.
For 8Lys8 and 10Lys10, the cloud point was shown to decrease with increasing surfactant 
concentration until a minimum value was reached. At this concentration, the cloud point 
increased with increasing surfactant concentration. Similar observations were made for 
LAM, in Paper III. The presence of a minimum CP has also been reported before for the 
EHEC/SDS system 86, 90, and it indicates a higher tendency for aggregation as the 
concentration is increased, possibly due to the formation of mixed aggregation sites and due 
to the high hydrophobicity of the long-chain surfactants. Only at sufficiently high surfactant 
concentrations, the charge repulsion effect becomes significant, inducing the repulsion 
between the polymer chains and causing the CP to increase. However, the cloud point of 
6Lys6 solutions remained unchanged at the measured range of concentration and 
temperature, which was related with the high hydrophilicity and low association tendency of 
this surfactant. Interestingly, none of the gemini arginine-based surfactants showed a 
significant decrease of CP at the gel-forming concentration range (1 x 10-3 to 1x10-2
mmolal, see star symbols in Figure 11 for GP), in spite of the presence of the long alkyl 
chains and hydrophobic spacer. This may be explained by the presence of two charged polar 
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head groups (instead of one, as in the Lys-based surfactants, Table 2, page 36). This causes 
a prominent charge repulsion effect, which balances the hydrophobic phenomena that are 
caused by the surfactant tails and by the association of EHEC at these temperatures. 
The CP was generally closely related with the estimated GP, due to the high connectivity of 
the system as the temperature is increased. In the vicinity of the gel point, small clusters of 
hydrophobic groups form, trigging an increase in the turbidity of the solution. In addition, 
the CP was always higher than the GP, suggesting the formation of turbid gels, with the 
exception of 6Lys6 (GP= 37.0 °C; CP=37.8 °C) and C6(LA)2 (GP= 36.5 °C; CP=37.5 °C) at 
the lowest concentration (Table 3). 
It is also worth discussing the relationship between structure and properties observed for the 
surfactants. As mentioned before, the different length of the alkyl chains in the Lys-based 
surfactants was shown to have a prominent effect on the viscosity profiles, GPs and CPs. 
For these surfactants, an increase in the alkyl chain length generally caused the 
viscosification, the sol-gel transition and the CP upturn to occur at lower concentrations. In 
contrast, this tendency was not very clear for the gemini Arg-based surfactants, in which the
increase in spacer length did not reveal a very pronounced effect over the measured 
rheological properties, since similar profiles were observed. However, the lower efficiency 
of the monomeric surfactant was clearly demonstrated, as pointed out previously. 
Surfactants, and, particularly, those bearing a positive or negative charge, are commonly 
observed to be environmentally toxic and poorly biocompatible and biodegradable 95. This 
is a major issue that compromises their use in biomedical and pharmaceutical applications. 
In this work, the investigation of the toxicological implications of the surfactants was 
therefore considered very important, having in mind a potential pharmaceutical use. The 
results for the in vitro experiments on a human epithelial cervical carcinoma cell line 
(HeLa) were presented and discussed in papers II and III. In Figure 12, a summary of the 
estimated EC50 values (concentration that induces a response halfway between the baseline 
and the maximum response) and the minimum effective surfactant concentration (MESC) 
that induces the thermoresponsive gelation of EHEC is presented.  
In Paper II, where the Lys-based surfactants were investigated, the EC50 values followed the 
tendency: 6Lys6 > 8Lys8 > 10Lys10, indicating that the toxicity increases with the alkyl 
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chain length, due to the increased hydrophobicity of the molecule and higher capacity to 
destabilize the biological membranes.  
In Paper III, it was not surprisingly shown that among the Arg-based surfactants, the 
monomeric LAM caused the lowest toxic effects (higher EC50), due to the presence of a 
single alkyl chain and only one charged group. This implies that the surfactant is less prone 
to disturb the cell membranes. In opposition, the higher hydrophobicity and charge density 
of the gemini counterparts causes them to be more cytotoxic.  
In short, surfactants with longer alkyl chains and with a dimeric structure were the most 
cytotoxic. However, these are also the most efficient and only very low amounts are needed 
in order to induce the temperature-responsive gelation of EHEC. In this context, it is 
imperative that the results are analyzed in terms of the relationship between the toxicity and 
the MESC. If one analyzes Figure 12, it is clear that 10Lys10, C6(LA)2 and C9(LA)2 were 
the only surfactants where the MESC was lower than the EC50. This suggests that the higher 
toxicity of the surfactants is considerably compensated by their enhanced efficiency at lower 
concentrations. Importantly, the same condition was not observed for the conventionally 
used surfactants SDS and CTAB (Figure 12). 
In addition, EHEC was not shown cytotoxic under the conditions of the in vitro experiment, 
and its presence was found to reduce the toxic effects of the surfactants. For instance, at the 
MESC of 6Lys6, cell viability increased from an average 49.9% to 90.8%, in the presence 
of the polymer (data presented in paper II). It is anticipated that in the presence of EHEC, 
the surfactant molecules preferentially interact with the polymer’s hydrophobic groups, 
forming mixed micelles, as discussed before for the gelation of EHEC in the presence of 
ionic surfactants. The lower availability of the surfactant in the medium makes it less 
available to interact with the cells, thereby contributing to a reduced toxicity. 
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Figure 12. EC50 values estimated for the amino acid-based surfactants on HeLa cells, and 
minimum effective surfactant concentration inducing the temperature-responsive sol-gel transition 
on 2 wt% EHEC solutions. EC50 and minimum effective concentration of SDS and CTAB from 
refs. 175 and 93, respectively.
From the point of view of the prospective pharmaceutical application of the EHEC-
surfactant systems, the following considerations can be made from the rheological and 
toxicological results: 
i. All systems demonstrated low viscosities at room temperature and formed gels at 
37 °C or close to body temperature. This means that the systems can constitute 
promising DDSs once injected, forming a depot in situ from which the drug can 
slowly be released. In case of sol-gel transitions at temperatures higher than body 
temperature, it is anticipated that the gel point can be tuned to lower values by 
increasing polymer concentration or the formulation composition; 
ii. The gels were in general soft, as revealed by the gel strength (S) values, which is 
expected to increase patient’s comfort at the injection site. In addition, the fractal 
dimension (df) values suggest that a relatively homogeneous network is formed 
at the gel point, indicating that the drug would be evenly distributed within the 
network. The drug retention properties should nonetheless be contemplated in 
future studies; 
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iii. The cloud point determinations suggest that most gels are turbid at the GP, 
which is reminiscent of the formation of small hydrophobic clusters in the 
network. In the context of a DDS, the hydrophobic microdomains can be 
interesting for the retention of hydrophobic drugs with low water solubility. 
However, because the cloud point is also indicative of the onset of phase 
separation 174, the long-term stability of the systems should be probed; 
iv. Surfactants with gemini-like structure were shown to be more effective, inducing 
gelation at lower concentrations than the monomeric LAM. Remarkably low 
surfactant concentrations are necessary for C6(LA)2 and C9(LA)2, which makes 
them particularly appealing from both the economical and the toxicological 
points of view; 
v. Among all EHEC-surfactant systems, formulations with C6(LA)2 showed the 
most promising results, since the GP is lower than body temperature (36.5 °C), 
and very low concentrations are needed to induce the sol-gel transition. In 
addition, the low turbidity suggests that gels with higher stability may be formed 
under these conditions. These gels also exhibited some of the highest values of S; 
vi. The higher efficiency of the long-chain and double-chained surfactants 
contributed to a lower toxicity in vitro, since the gelation takes place at very low 
concentrations. This also confirms that these surfactants are the most promising 
for pharmaceutical applications. In vitro studies on other cell lines and in vivo
experiments should be performed so as to confirm the biocompatibility of the 
hydrogels. 
vii. Finally, it cannot be disregarded that the rheology data were acquired in water, 
and that different observations can be made when the medium is replaced with 
the isotonic injectable solution. Further experiments should be carried out to 
accommodate for this issue. 
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5.2 Microparticles as controlled drug release systems 
Bearing in mind the development of a DDS that allows for a long-standing effect, it was 
hypothesized that suspending polymeric drug-loaded microspheres in a temperature-
responsive hydrogel could significantly contribute to control the drug release. In other 
words, the microspheres would be the first barrier, from which the drug could be released by 
diffusion and matrix erosion phenomena, while the gel should be able to confine the 
microparticles and further reduce the drug release rate. This combined system is illustrated 
in Figure 13.  
Preliminary experiments concerning the production and development of polymeric 
microparticles are described in Paper IV. 
Figure 13. Two-component system involving drug-loaded microparticles and a suspension 
medium that forms a gel after injection, due to the higher temperature in situ.  
In order to fulfill these objectives, three different polymers were tested as polymeric 
matrices for microparticulate systems (Table 1, page 34), with particular emphasis being 
given to a hydrophobically-modified chitosan derivative (HM-chitosan). Naltrexone (NTX), 
an opioid antagonist, was used as a model drug. 
Chitosan is a cationic polysaccharide that has been widely used in DDSs such as nano and 
microparticles 176-179. Chitosan is highly biocompatible and biodegradable and its 
degradation products are nontoxic 180, 181. Its bioadhesive character, immunostimulating 
activity and antimicrobial properties are also well-known 181. In drug delivery, chitosan 
demonstrates a high ability to control the release of the active agents. In addition, the drug 
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encapsulation typically does not require the use of harsh solvents, since the polymer is 
soluble in aqueous acidic solution. Importantly, the polymer contains a number of free 
amine groups that can be cross-linked for an improved stability of the DDS 181. These free 
amine groups allow the chemical cross-linking of the matrix, thereby improving the stability 
and strength of the matrix 181, 182. However, chemical cross-linkers (e.g. glutaraldehyde) are 
usually toxic 182.  
In contrast, the hydrophobic modification of chitosans has been suggested to improve the 
stability of the polymer, while retaining its biocompatibility and biodegradability 183, 184. In 
this thesis, this principle motivated the use of a hydrophobically modified chitosan 
derivative, prepared by chemical modification of the amine groups on the polymer chains 
with a C12 aldehyde (Table 1). By doing so, it was expected that the drug-loaded 
microparticles showed enhanced stability and control release properties.  
For the matter of comparison, PLGA microparticles were produced in a similar way, due to 
the broad use of this polymer in DDSs such as micro and nanoparticles, pellets, films, 
implants and in situ-formed devices 128, 185. PLGA is approved by the Food and Drug 
Administration, due to its biodegradability and biocompatibility, stability, mechanical 
properties and ease of processing 185. 
Spherical and polydisperse particles were produced in most cases and the size 
measurements revealed that they were generally smaller than 50 μm. However, the 
multivariate analysis demonstrated that larger sizes were obtained if high HM-chitosan 
concentrations were used (up to 350 μm), due to the high viscosity of these solutions, 
making the droplets in the emulsion difficult to divide by the shear forces. The formation of 
large particles was also shown to be favored by the evaporation at high temperatures, which 
causes the particles to solidify rapidly. Other factors evaluated in the experimental design, 
namely needle diameter and stirring speed during the emulsification were not found 
significant in the planned experimental domain. 
The encapsulation efficiency (EE) of naltrexone was higher when HM-chitosan was used as 
a polymeric matrix (86.5% in the best case), than when chitosan and PLGA were employed. 
This high EE is probably related with the amphiphilic nature of HM-chitosan. Particularly, it 
is anticipated that the C12 groups are involved in hydrophobic associations with the drug, 
thereby contributing to a superior retention of NTX within the matrix.  
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Importantly, HM-chitosan demonstrated the highest drug retention properties in release 
experiments performed in vitro. After a small burst release during the first 6 hours, NTX 
was very slowly and continuously released for at least 50 days (Figure 14). This slower 
release rate is also probably related with the presence of the C12 groups that act as cross-
linkers due to the hydrophobic associations, and due to polymer-drug associations, as 
discussed previously. Furthermore, it is likely that the higher hydrophobicity of this polymer 
in relation to chitosan, contributes to reduce the water penetration. The drug release rate 
from HM-chitosan microparticles was further reduced when the particles were prepared at 
high temperatures, which suggests that compact structures of low porosity are formed under 
these conditions. 
Figure 14. In vitro NTX release from chitosan, HM-chitosan and PLGA microparticles  
(particles prepared at 1.5 wt% and at 60 °C for chitosan and HM-chitosan, and 25 °C for PLGA). 
In a context of the development of an injectable formulation allowing for a long-standing 
effect, stability and in vitro release studies should be carried out, namely by combining the 
temperature-responsive hydrogel with the drug-loaded microparticulate system. The results 
described in Paper IV showed that the conditions used in the preparation of the 
microparticles should be carefully considered, since they can significantly affect the EE and 
drug release properties of the system.  
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5.3 PNIPAAM-b-PAMPTMA(+) copolymers as gene carriers 
In this thesis, a selection of cationic polymers, synthesized or modified by the Polymer 
Chemistry Group, University of Oslo, were screened with respect to their potential as 
carriers for pDNA. These polymers included cationic hydroxyethyl cellulose (HEC+) 
(MW=400,000), hydrophobically-modified HEC+ (MW=400,000), poly-ȕ-cyclodextrin 
(poly-ȕ–CD) (MW=280,000) and poly(N- isopropylacrylamide)n-block-poly((3-
acrylamidopropyl)trimethylammonium chloride)m (PNIPAAMn-b-PAMPTMA(+)m) block 
copolymers (Table 1). The preparation conditions of the polyplexes and the procedure 
details for the transfection of HeLa cells are described in ‘Experimental considerations’ and 
in Paper V. 
The screening experiments revealed that both HEC+ and poly-ȕ–CD were mostly 
unsuccessful gene carriers, since 6% and 11% were the maximum transfection efficiencies 
estimated for the former and the latter, respectively. No gene delivery activity was detected 
for HM-HEC+. The assumption is that the high molecular weight of these polymers 
compromised the formation of small, compact structures and the transport across the 
plasma membrane. It is also possible that these polymers form very strong polyplexes with 
DNA, delaying its release, or that the polyplexes aggregate, as observed for high molecular 
weight chitosans 186 . 
In contrast, the temperature-responsive PNIPAAM-b-PAMPTMA(+) block copolymers 
were shown to successfully deliver the pDNA into the nucleus of HeLa cells, as assessed by 
the detection of GFP by flow cytometry. These block copolymers combined the 
thermoresponsive properties of PNIPAAM with the polycationic character of PAMPTMA. 
The four block copolymers were distinct in terms of the length of the two blocks, and so 
these differences were assessed with regard to the resulting polyplex structures and 
transfection potential. The increase in the length of the charged PAMPTMA further resulted 
in the increase of the LCST of the polymer, as shown in Table 1 (page 34). 
It was hypothesized that the presence of the positively charged block could allow the 
interaction with the oppositely charged DNA through electrostatic interactions, in a process 
that is facilitated by incubation at room temperature (< LCST), due to the expansion of the 
polymer chains at this temperature. Furthermore, the temperature-responsive properties of 
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PNIPAAM at 37 °C were theorized to contribute to form compact particles in contact with 
the cells, while the resulting positively charged surface is known to facilitate the adherence 
to cell surface and the endocytic process 146. The principles supporting the complex 
formation and nanoparticle uptake by HeLa cells are illustrated in Figure 15. 
Figure 15. Suggested model leading to complex formation, cell interaction and uptake, using PNIPAAM-b-
PAMPTMA(+) block copolymers. 
The results were shown to depend on the N/P charge ratio and on the type of polymer 
(Figure 16).  In general, low N/P ratios resulted in very low transfection efficiency, due to 
the absence of a positively charged surface (confirmed by zeta potential measurements). In 
contrast, at higher N/P ratios, the DNA is coated and protected from the action of nucleases 
and the overall charge density increases, facilitating the adsorption and uptake of the 
polyplexes by the cells.   
Polyplexes containing the longest PNIPAAM (PNIPAAM65-b-PAMPTMA(+)20) were the 
most effective gene carriers. When the PNIPAAM length was kept constant (PNIPAAM48), 
the transfection efficiency essentially followed the sequence PAMPTMA(+)6 > 
PAMPTMA(+)10 > PAMPTMA(+)20, showing that the process is favored by the presence of 
a shorter charged block.  
However, in the cases where higher transfection efficiency was observed, the cell viability 
was found to decrease. At an N/P ratio of 20/1, the transfection efficiency was 64.4 ± 2.8% 
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for PNIPAAM65-b-PAMPTMA(+)20 and 61.2 ± 7.6% for PNIPAAM48-b-PAMPTMA(+)6, 
with a cell viability of 41.2 ± 3.5% and 56.2 ± 3.6%, respectively. At the highest N/P ratio 
(30/1), the 65:20 block copolymer transfected 80.8 ± 4.5% of the cells, and the cell viability 
was 30.5 ± 1.7%. 
Figure 16. Transfection efficiency and viability of HeLa cells after treatment with the polyplexes.  
The postulated structures formed by the polyplexes at 37 °C are shown in the inset. 
This work demonstrated that the composition and molecular weight of the polymers has an 
important effect on the gene delivery efficiency and associated toxicity. Since temperature-
dependent structural modifications were expected at the incubation temperature, 
physicochemical data concerning the thermosensitive behavior of the polyplexes in solution 
were acquired (zeta potential, size and turbidity), so as to build polymer-DNA structural 
models. These models are shown in the insets in Figure 16.  
The most efficient carrier, i.e. PNIPAAM65-b-PAMPTMA(+)20 was characterized by 
forming small (100-300 nm), closely packed polyplexes, and by the presence of a highly 
charged corona around the condensed PNIPAAM core. In this case, the formation of the 
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closely packed core was associated with the very long PNIPAAM and with a high degree of 
hydrophobic associations taking place at 37 °C (CP estimated as 34 °C, Table 1, page 34).  
Among the polymers with a similar PNIPAAM length, the polymer containing the smallest 
PAMPTMA(+) (n:m = 48:6) led to the highest transfection efficiency, as mentioned 
previously. Here, the presence of a very short charged block was insufficient to cause 
charge repulsion and larger structures were formed (approx. 400 nm). Nonetheless, the high 
association tendency of the polymer led to the formation of compact polyplexes, as assessed 
by turbidity measurements. As in the former case, it is likely that the compact core was 
decorated with positive charges (zeta potential at 37 °C of +20 to +25 mV depending on N/P 
ratio). The combination of these features is expected to have contributed to a higher 
adsorption to the cell surface and to the cell uptake and endosomal escape. 
Compact systems such as those made from the two former polymers are further expected to 
cause the inclusion of the DNA, which enhances the protection effect against the damaging 
action of nucleases. Experiments with Picogreen dye (method for quantifying double-
stranded DNA in solution) revealed that the polymers effectively protected the DNA from 
the external environment, even when the lower polymer concentrations were used (methods 
and data shown in Paper V). 
In contrast, when the length of PNIPAAM was kept constant, polymers with longer 
PAMPTMA(+) blocks (PNIPAAM48-b-PAMPTMA(+)10 and PNIPAAM48-b-
PAMPTMA(+)20) were the poorest gene carriers (Figure 16). This is because the long 
PAMPTMA(+) blocks cause some electrostatic repulsion between polymer chains, 
inhibiting to some extent the hydrophobic association of the chains into a compact structure. 
As a consequence, the CP of the polymers increases (Table 1, page 34). In the extreme case 
of PNIPAAM48-b-PAMPTMA(+)20, the compactness and hydrophobicity of the core is the 
lowest, making the transfection a very difficult process. For this reason, no levels of 
transfection are detected, except when very high polymer concentrations are used with 
respect to the DNA payload (N/P = 30/1). 
Overall, the results showed that the polymers effectively protected the DNA from the 
external environment, and that the payload can be delivered into the nucleus, where the gene 
that codes for GFP was expressed. However, the production of compact particles that 
condense the DNA seems to be a prerequisite for an efficient transfection. 
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In view of a prospective use of the PNIPAAM-b-PAMPTMA(+) block copolymers in gene 
therapy, this work also demonstrated that the molecular weight and the hydrophilic-
hydrophobic balance of the copolymer should be carefully planned, so as to ensure that 
compact particles are formed at physiological temperature. Furthermore, an adequate 
polymer/DNA ratio can contribute to increase the transfection efficiency with low
cytotoxicity levels. One very appealing advantage of the use of PNIPAAM-b-
PAMPTMA(+) copolymers is that the formation of nanoparticles and entrapment of DNA 
can be achieved by simply increasing the temperature above the LCST of the polymer. 
Kurisawa et al. demonstrated that the gene delivery efficiency of temperature-responsive 
polymers can be improved by momentarily lowering the incubation temperature below the 
LCST during transfection. In this article, the authors related the increased transfection 
efficiency with the dissociation of the complexes at lower temperatures 187. Takeda et al. 
similarly showed that the DNA could be released from temperature-responsive polymers by 
decreasing temperature 188. These authors further addressed the potential of these polymers 
as gene delivery carriers to the epidermal region (by employing a skin cooling procedure), 
or to the internal organs, if a cooling catheter is used. In a similar fashion, it is expected that 
higher transfection efficiencies are achieved if a cooling step is included in the transfection 
protocol involving the PNIPAAM-b-PAMPTMA(+) block copolymers. Ultimately, in an 
optimized system, an increase of the transfection efficiency can imply a decrease in the 
necessary amount of polymer, which contributes to decrease the cytotoxicity levels. Future 
work should therefore accommodate for these hypotheses.  
In addition, it is known that the presence of anionic serum proteins can affect the stability of 
the polymer/DNA complexes and result in reduced endocytosis 189, 190. Due to the 
importance of this effect in vivo, the sensitivity of the polyplexes to the presence of serum 
should be investigated in future studies.  
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Concluding Remarks 
First of all, this work demonstrated that thermoresponsive hydrogels can be developed by 
combining EHEC with lysine- or arginine-based surfactants. The polymer solutions 
generally show a low viscosity at room temperature and a viscosification at higher 
temperatures. At specific surfactant concentrations, a sol-gel transition is observed, 
demonstrating the potential of the solutions as in situ gelling systems. Among all the tested 
surfactants, those with longer alkyl chains and with a dimeric structure are the most 
efficient, modulating the temperature-responsive gelation of EHEC at very low 
concentrations. The produced gels are mostly soft but relatively homogeneous. 
Furthermore, in vitro toxicity studies demonstrated that the most effective surfactants are 
also the most cytotoxic, as evaluated by the estimated EC50 values. However, the toxicity of 
these surfactants in the presence of EHEC is significantly reduced. In addition, the fact that 
remarkably low amounts of the long chain or gemini-like surfactants are needed in order to 
produce the gels significantly contributes to decrease the overall cytotoxicity of the system.  
In the context of the development of a DDS allowing for a long-term drug delivery, it is 
proposed that the thermoresponsive hydrogel can be combined with drug-loaded 
microparticles. Spherical particles, smaller than 50 μm, are in general formed by the 
emulsification-solvent evaporation method. Among the three polymers evaluated, chitosan 
and HM-chitosan demonstrate higher production yield, while the latter also shows superior 
efficiency in encapsulating naltrexone. When HM-chitosan is employed, larger particle size 
can be achieved if high concentrations are used, and if the solvent is evaporated at high 
temperatures. Ultimately, particles formed by this polymer also show the highest control of 
drug release.  
In this thesis, it was also shown that DNA-polymer complexes prepared from PNIPAAM-b-
PAMPTMA(+) block copolymers effectively carry the nucleic acids to the cell nucleus, 
suggesting a potential use of these thermoresponsive polymers in gene delivery applications. 
The transfection efficiency is however highly dependent on the molecular weight and 
hydrophilic-hydrophobic balance of the copolymer, and on the polymer/DNA ratio.  
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Polymers containing the longest PNIPAAM block or the shorter PAMPTMA(+) are the 
most effective gene carriers, due to the strong PNIPAAM aggregation at 37 °C. These 
structures have a hydrophobic PNIPAAM core and a positively charged corona, and were 
demonstrated to efficiently protect the DNA from the external environment. 
In cases where a high transfection is observed, high cytotoxicity levels are also observed. 
This emphasizes the importance of controlling the structure of the polymers and the 
polymer/DNA ratio, so as to achieve an optimal result. 
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Future Studies 
In this thesis, the first steps towards the development of new drug and gene delivery systems 
are described. To further explore these systems, additional experiments are suggested. 
With regard to the thermoresponsive hydrogel, rheological studies should be carried out in 
the isotonic injectable solution intended for pharmaceutical use. It is also suggested that the 
polymer concentration is modified in order to produce gels with a phase transition 
temperature appropriate for human use.  Once the mechanical properties of the gel are 
optimized, its stability should be evaluated in a buffer environment. Ultimately, a binary 
system combining drug-loaded microparticles and the thermoresponsive hydrogel should be 
evaluated in vitro in terms of its pharmacokinetic profile and potential for long-term 
applications. In this respect, HM-chitosan microparticles may be preferably studied, due to 
the high drug retention capacity shown in this work. 
Taking into consideration a prospective use of the PNIPAAM-b-PAMPTMA(+) block 
copolymers in gene delivery, further studies should be carried out in other cell lines. Studies 
on polymers with different molecular weight and block length may allow for the 
optimization of the system in terms of the balance between high transfection efficiencies 
and low cytotoxicity. In one alternative approach to the protocol used in this thesis, a 
cooling step can be introduced in the transfection method, so that complex dissociation is 
promoted, thereby increasing the transfection efficiency. Furthermore, transfection studies 
should be carried out in the presence of serum, with the purpose of more closely mimicking 
the in vivo milieu conditions.  
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ABSTRACT: In this work, a hydrophobically-modified (HM) chitosan derivative was 
prepared by covalent linkage of C12 groups to the chitosan backbone. HM-chitosan 
microparticles were prepared according to an emulsification-solvent evaporation method and 
naltrexone (NTX) was used as a model drug. For comparison, unmodified chitosan and poly 
lactic-co-glycolic acid (PLGA) microparticles were also tested as carriers for NTX.  
HM-chitosan formed viscous semi-dilute solutions, suggesting a high level of chain 
entanglements and hydrophobic associations. HM-chitosan microparticles generally showed 
higher production yield and encapsulation efficiency, as compared to chitosan and PLGA. At 
pH 7.4, the burst release shown by chitosan microparticles was significantly reduced when 
using the HM-chitosan derivative. Reduced release rate from the HM-chitosan microparticles 
was further favored when these were prepared at a higher temperature. An enhanced control 
of drug release was observed over at least 50 days. PLGA particles demonstrated inferior 
controlled release properties as compared to HM-chitosan subsequent to the initial release 
stage. 
These results revealed the potential of hydrophobic modification of chitosan as a means to 
improve the stability and sustained delivery properties of the polymer. HM-chitosan could 
thus be a promising carrier for drugs such as NTX. 
Keywords: Chitosan, biomaterials, hydrophobic modification, microparticles, factorial 
design, controlled release
INTRODUCTION 
Chitosan is a natural cationic polysaccharide derived from 
the deacetylation of the naturally occurring chitin. It is a 
linear copolymer composed of ȕ-(1,4)-linked 2-acetamido-
2-deoxy-ȕ-D-glucopyranose and 2-amino-2-deoxy-ȕ-D-
glycopyranose.1 This homo-polymer is soluble in water at 
low pH, due to the protonation of the free amine groups.2 In 
addition, the excellent biocompatibility and biodegradability 
properties of chitosan make this a particularly appealing 
material for pharmaceutical and biomedical applications. Its 
degradation products, amino sugars, are also non-toxic and 
completely absorbed by the human body.1,2  
Chitosan has been extensively used in drug delivery 
systems, such as nanoparticles and microparticles,3-6 where 
the controlled delivery of encapsulated or entrapped active 
agents has been demonstrated. In addition, chitosan is 
recognized for its mucoadhesiveness to epithelial tissues.1
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The presence of free amine groups additionally allows the 
chemical cross-linking of the matrix with agents such as 
glutaraldehyde,2,5,7,8 which contributes to increase the 
stability and strength of the network. However, the use of 
such cross-linkers has been questioned due to toxicity 
concerns.5 Another approach has been to physically cross-
link the polymer with ionic molecules such as the anionic 
tripolyphosphate (TPP).9,10 In spite of the lower toxicity of 
the ionic cross-linkers, the cross-linking density of the 
network can change significantly in vivo in response to pH 
changes. Physically cross-linked chitosan networks may 
also lack mechanical stability and dissolve rapidly, which 
seriously compromises their use in long-term applications.10
Hydrophobically modified chitosans can show excellent 
biocompatibility and biodegradability in vivo, and form high 
stability systems.11,12 The presence of hydrophobic moieties 
makes these polymers very appealing as drug delivery 
systems for poorly water-soluble drugs.11-13 It has been 
shown that hydrophobically modified chitosans can self-
assemble into nanoparticles with a hydrophobic core, 
improving the encapsulation efficiency and release profile 
of hydrophobic drugs.11-14
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Tien et al.15 also reported that N-acetylated chitosans with 
long chain side chains (C8-C16) showed improved 
mechanical properties and drug release features when used 
in tablets, which was attributed to the establishment of 
hydrophobic interactions between side chains. Furthermore, 
the authors suggested that as the length of the side chains 
increased, the swelling degree of the matrices decreased, 
causing the drug release to depend mostly on diffusion.15
Water-soluble hydrophobically modified chitosans are 
therefore an innovative field with great potential in drug 
delivery. In this work, a hydrophobically modified chitosan 
(HM-chitosan) was produced by chemical modification of 
the amine groups on the polymer chains with a C12 aldehyde 
(Figure 1 a.). The potential of this modified polymer in 
controlled drug delivery was investigated by formulating 
microparticles containing the model drug naltrexone (NTX). 
Throughout the study, HM-chitosan particles were 
compared with counterparts based on an unmodified 
chitosan and on poly lactic-co-glycolic acid (PLGA), 
allowing estimation of the effect of increasing the 
hydrophobicity of chitosan, and comparison with an 
established hydrophobic polymer. 
The work described here is part of a broader project in 
which the ultimate aim is to develop a two-component 
formulation involving drug-loaded microparticles and a 
thermoresponsive suspension medium that forms a gel in 
situ, once injected. Through this combination, it is 
anticipated that the control of drug release is highly 
improved, as shown previously for analogous 
formulations.16 Even though the work presented in this 
article is strictly related with the development of the 
microparticulate system, studies on low toxicity 
thermosensitive gel systems have also been carried out by 
our group.17-19 
Figure 1. a. Molecular structure of chitosan and HM-chitosan.  
Chitosan: R= NH2 or R= NH-CO-CH3; HM-chitosan: R=NH2 or 
R=NH-CO-CH3 or R= N=CH-C11H23. b. Structure of naltrexone 
(NTX).
MATERIALS AND METHODS
Materials
The hydrophobically-modified chitosan (HM-chitosan) was 
prepared by modification of a chitosan sample (Pronova 
Biopolymers, Norway) by reaction of the amine groups on 
the polymer chains with a C12 aldehyde (Figure 1 a.).  
The unmodified chitosan had a degree of N-deacetylation of 
84% and a molecular weight of 400 kDa. The degree of C12-
aldehyde substitution in HM-chitosan was 5 % with respect 
to free amine groups. Details on the modification can be 
found elsewhere.20
The unmodified chitosan used in this study had a degree of 
deacetylation of 75-85% and a molecular weight of 300-500 
kDa (information provided by the manufacturer, Sigma-
Aldrich, USA). PLGA (RESOMER® RG 502), ester 
terminated, (lactide:glycolide (LA/GA) 50:50), Mw 70-
17,000 was obtained from Aldrich (USA). Naltrexone, USP 
Reference Standard (Rockville, MD) was used as a model 
drug (Figure 1 b.).  
Rheology measurements
Viscosity measurements were performed in a Paar-Physica 
MCR 301 rheometer (Physica Messtechnic GmbH, 
Germany) using a cone-and-plate geometry, with a cone 
angle of 1o and a diameter of 75 mm. Temperature control 
was ensured by a temperature unit (Peltier plate). Chitosan 
and HM-chitosan samples were dissolved in 1% (v/v) acetic 
acid at a concentration of 0.5, 1.0 or 1.5 wt%. The samples 
were introduced onto the plate and a thin layer of low 
viscosity silicone was added to the free surface of the 
sample to prevent evaporation during the measurements. 
Preparation of blank microspheres 
Chitosan, HM-chitosan and PLGA microspheres were 
prepared by an emulsification-solvent evaporation method, 
as briefly described below.  
Chitosan and HM-chitosan were dissolved in 3.3-10 ml of 
1% (v/v) acetic acid, depending on concentration (indicated 
in Table 1). The polymer solution was added dropwise to 
the continuous phase comprising of 50 g liquid paraffin and 
0.7 wt%  sorbitan monooleate as emulsifier. Addition of the 
polymer solution was performed through a needle of 
specific diameter, while the continuous phase was kept 
under constant stirring (Eurostar power control-visc stirrer, 
IKA-WERKE, Germany). The stirrer was connected to a 
Neslab RTE-101 thermostat (Neslab Instruments, USA), 
allowing temperature control of the process. Stirring 
continued for a minimum of 5 hours in order to ensure 
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complete evaporation of the aqueous solvent. At the end, the 
microspheres were extensively washed with petroleum ether 
and recovered by vacuum filtration through a 0.8 μm pore 
size membrane filter (MF-Millipore Membrane, mixed 
cellulose esters, Millipore, USA). 
When producing PLGA microparticles, the polymer was 
dissolved in dichloromethane. The polymer solution was 
added as described before to the continuous phase, which in 
this case consisted of an aqueous polyvinyl alcohol (PVA) 
solution (0.5 wt%). In the final step, the PLGA particles 
were thoroughly washed with water and vacuum filtered as 
described previously. 
According to a planned experimental design, four 
experimental parameters were varied during the 
emulsification process: i) polymer concentration, ii) needle 
diameter, iii) stirring speed and iv) temperature. The details 
are described in the following section.
Experimental design and multivariate analysis 
The effects of the four formulation factors at two levels 
were investigated in a reduced factorial 24-1 design with 
three center points. Subsequent to preliminary multivariate 
evaluation, the design was extended. The factors and levels 
of the experimental design are shown in Table 1.  
Once all batches were prepared, the size and size 
distribution of the microspheres was analyzed (see section 
‘Size and morphological features of naltrexone-loaded 
microspheres’ for procedure details). 
Multiple linear regression (MLR) was used (Modde 5.0, 
Umetrics AB) to evaluate the effects of the variables on the 
particle size. The initial fitting was performed on a full 
model with maximum available main factors and 
interactions, followed by stepwise backward elimination of 
the least significant regression coefficients until only 
significant coefficients remained (p<0.05). The statistical 
significance of the model and individual regression 
coefficients were evaluated by Analysis of Variance 
(ANOVA). 
Table 1. Experimental design for the preparation of the blank-
microspheres.
Factors Low Level High level 
Polymer concentration (wt %) 0.5 1.5 
Needle diameter (mm) 0.5 1.1
Stirring speed (rpm) 700 900 
Temperature (°C)a 30 60 
a In the case of preparation of PLGA microspheres, the low and 
high level were 5 and 25 °C, respectively. 
Preparation of naltrexone-loaded microspheres 
Suitable conditions indicated by the preparation of blank 
microspheres (selected after multivariate analysis – Table 1) 
were used to prepare the naltrexone-loaded samples. In this
case, stirring speed was kept at 750 rpm and all polymer 
solutions were added dropwise to the continuous phase 
through a 0.5 mm diameter needle. The drug was dissolved 
together with the polymer (50% drug:polymer mass ratio). 
The preparation conditions of the different naltrexone-
loaded samples are shown in Table 3. 
From hereafter and in order to clarify the text for the reader, 
each sample will be shortly named according to the polymer 
used (C for chitosan, HM for HM-chitosan and P for 
PLGA), polymer concentration (L for low=0.5 wt% and H 
for high=1.5 wt%) and preparation temperature (indicated 
by the last number, i.e. 5, 25, 30 or 60 °C). The subsequent 
preparation steps of the NTX-loaded microparticles 
essentially followed the procedure described above for the 
blank microparticles. 
The yield of production of NTX-loaded microparticles was 
estimated as follows: 
ܻ݈݅݁݀Ψ ൌ ݓ݄݁݅݃ݐ݋݂݈݊ܽݐݎ݁ݔ݋݊݁ܽ݊݀݌݋݈ݕ݉݁ݎ݅݊݅ݐ݈݈݅ܽݕݑݏ݁݀ݓ݄݁݅݃ݐ݋݂݌ݎ݋݀ݑܿ݁݀݌ܽݎݐ݈݅ܿ݁ݏ݂ܽݐ݁ݎ݀ݎݕ݅݊݃ ݔͳͲͲ
Size and morphological features of naltrexone-
loaded microspheres 
Size and size distribution were evaluated by suspending a 
small amount of microspheres in ethanol, so that particle 
concentration was lower than the instrument’s threshold for 
individual detection of the particles. Samples were stirred 
for a few minutes in order to ensure homogenization and 
dispersion of aggregates.  The analysis was performed using 
an Accusizer 780 (Optical Particle Sizer, PSS NICOMP, 
Santa Barbara, California, USA). Size parameters, i.e. mean, 
standard deviation (SD), mode and median were 
determined. For particles larger than 2.5 μm, the median 
volume was also calculated. 
The morphological features of the microspheres were 
evaluated by scanning electron microscopy (SEM). Samples 
were sprinkled on carbon taps mounted on aluminum stubs 
followed by sputtercoating with 5 nm platinum in a 
Cressington 308 UHR Coating System. Samples were 
imaged in a Hitachi S-4800 FE SEM at 1.0 kV and a 
working distance of 2.5 mm. 
Drug content: encapsulation efficiency and loading 
capacity
In order to determine the drug content present in chitosan 
and HM-chitosan microspheres, an accurately weighed 
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amount of microspheres (3-5 mg) was firstly suspended in 
ethanol, in order to facilitate the dispersion of aggregates. 
The microspheres were subsequently dissolved in 0.1 N 
hydrochloric acid (pH 1) by vigorously stirring the samples 
at room temperature for 4 days. Samples were filtered 
through a 0.22 μm syringe filter (Millex, Millipore, Ireland). 
Naltrexone was released from PLGA microspheres by 
dissolving the polymer in dichloromethane. The amount of 
drug released was quantified by measuring the absorbance 
of the solution at 282 nm, using a Spectronic Helios Gamma 
spectrophotometer (Thermo Fisher, UK). 
The encapsulation efficiency (EE) and loading capacity 
(LC) of the microspheres were calculated as follows: 
ܧܧሺΨሻ ൌ ݉݁ܽݏݑݎ݁݀ܽ݉݋ݑ݊ݐ݋݂ܰܶܺ݅݊݉݅ܿݎ݋ݏ݌݄݁ݎ݁ݏݐ݋ݐ݈ܽܽ݉݋ݑ݊ݐ݋݂ܰܶܺܽ݀݀݁݀݀ݑݎ݅݊݃݉ܽ݊ݑ݂ܽܿݐݑݎ݅݊݃ ݔͳͲͲ
ܮܥሺΨሻ ൌ ݉݁ܽݏݑݎ݁݀ܽ݉݋ݑ݊ݐ݋݂ܰܶܺ݅݊݉݅ܿݎ݋ݏ݌݄݁ݎ݁ݏݓ݄݁݅݃ݐ݋݂݉݅ܿݎ݋ݏ݌݄݁ݎ݁ݏ ݔͳͲͲ
In vitro release experiments 
The in vitro release experiments were carried out in 
phosphate buffered saline (PBS), pH 7.4, prepared 
according to the European Pharmacopoeia21 and adding 
0.02% sodium azide, to prevent bacterial growth during the 
experiment. NTX-loaded microspheres were accurately 
weighed (10 mg) and transferred to a dialysis tube 
(Spectra/Por MWCO 50,000, Spectrum Laboratories, USA). 
400 µl of PBS were carefully added to suspend the particles. 
The dialysis tube was placed in a stoppered vial containing 
25 ml of PBS solution, ensuring sink conditions. The vials 
were further positioned inside a water bath connected to a 
thermostat, keeping the temperature at 37 °C. Samples were 
stirred throughout the experiment by a 15-position magnetic 
stir plate (RO15 power, IKA, Germany), placed beneath the 
water bath (position 2, ~100 rpm). 
At specific time intervals, the absorbance of the buffer 
solution was measured at 282 nm, using a UV Ultrospec II 
spectrophotometer (LKB Biochrom, UK).  
RESULTS AND DISCUSSION
Viscosity measurements of chitosan and HM-
chitosan solutions 
In the emulsion-solvent evaporation method, one of the 
critical factors that define the size of the droplets in the 
emulsion is the viscosity of the dispersed phase. The general 
tendency is that high viscosity solutions are more difficult to 
disrupt into small droplets, thereby yielding larger 
particles.22 In this work, the viscosities of chitosan and HM-
chitosan solutions were determined at different 
concentrations and temperatures, as shown in Figure 2.
First of all, it is obvious that chitosan solutions are less 
viscous than the corresponding ones prepared using HM-
chitosan. This effect is very prominent for the highest 
polymer concentration (1.5 wt%). The viscosity of semi-
dilute solutions of unmodified- and HM-chitosan samples 
has previously been attributed to both entanglement effects 
and hydrophobic associations.20,23 The viscosity has also 
been shown to increase as the hydrophobicity of the 
polymer increases, due to the high tendency of the 
hydrophobic groups to associate.20,23 The association of the 
hydrophobic moieties results in aggregates that act as cross-
links between the polymer chains, causing the formation of 
an interconnected network.24,25
Figure 2 also shows that, in most cases, the viscosity 
decreased with increasing temperature. This is explained by 
the fact that the intermolecular associations are broken to 
some extent at higher temperatures, due to the enhanced 
mobility of the chains.23 However, the viscosity of the HM-
chitosan sample prepared at a concentration of 1.5 wt% is 
less affected by the temperature increase, because of strong 
entanglements and association effects.
Experimental design and multivariate analysis 
Blank polymeric microspheres were prepared by an 
emulsification-solvent evaporation method, using different 
conditions, as summarized in Table 1. 
Chitosan, HM-chitosan and PLGA samples prepared 
according to the experimental design were compared in 
terms of the size parameters. The control of particle size was 
deemed very important, since this parameter can have a 
crucial effect over the particles’ degradation profile,26
loading and encapsulation efficiency27 and drug release 
rate.28
The investigated factors were hence chosen based on their 
possible effect on particle size. It has been shown, for 
instance, that smaller particle sizes may be obtained by 
using low polymer concentrations. Low viscosity of the 
solutions causes them to be easily separated into small 
droplets by shear forces29 leading to reduction of the final 
particle size. Temperature may consequently also be an 
important parameter, due to its effect on the viscosity of the 
polymer solution, while the stirring speed can be 
determinant of the size of the droplets.29,30 Apart from 
polymer concentration, temperature and stirring speed, we 
also investigated the effect of needle diameter on particle 
size, since it was hypothesized that the initial droplet size of 
the emulsion could affect the final particle size. 
As the size distributions of blank microparticles were 
generally observed to be bimodal, the size parameters were 
estimated separately for two regions, above and below 2.5 
μm, where nearly all the curves exhibited a minimum. 
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Figure 2. Temperature-dependencies of the shear viscosity of chitosan and HM-chitosan solutions prepared 
in 1% (v/v) acetic acid at the polymer concentrations of 0.5, 1.0 and 1.5 wt% (shear rate 0.4 s-1). 
It is clear that the type of polymer affected the size 
distribution of the particles. In this respect, chitosan 
microparticles were generally shown to have the largest 
proportion of particles larger than 2.5 μm, whereas the 
differences between HM-chitosan and PLGA microparticles 
were not found significant (analysis of variance followed by 
a post hoc Tukey’s test).
Looking at the individual polymers and size parameters for 
the chitosan and PLGA particles, no significant effects of 
the formulation factors were observed. Even though this 
might indicate a robustness of the process, it is likely that 
different results might have been obtained if the 
experimental domain had been increased (Table 1). 
However, this was not the purpose of this study, but rather 
to screen for possible important process factors within 
reasonable limits and obtain an insight into the inter-batch 
variation.  
In contrast to the other polymers, the production of HM-
chitosan microparticles was found to be significantly 
affected by polymer concentration (Figure 3, Table 2) and to 
some extent temperature (Table 2). 
An interesting observation is that the effect of HM-chitosan 
concentration showed an opposite trend for the lower and 
higher size region, i.e. increasing polymer concentration 
reduced the size of the small particles and increased the 
mean size of the large particles (Figure 3).  
The effect on the large particles is as expected, since the 
concentration-induced viscosification promotes the 
formation of larger particles. The effect of the high 
concentration on the smaller particles may be explained by 
the high viscosity of the solution and lower solubility of the 
polymer in the dispersed phase, causing the polymer to 
precipitate faster on the droplets’ surface, and limiting the 
coalescence between droplets.  
For some of the models, Lack of Fit was observed, 
indicating possible additional significant terms. However, 
such terms would be interactions or squared terms that are 
not possible to estimate with the present screening design. 
The initial screening of the blank microspheres focused on 
size but it is also well-known that the density and/or 
porosity of the microspheres can significantly affect the 
drug release rate.31 Bearing in mind this principle and 
considering the factors significantly affecting the blank 
microspheres (concentration and temperature), formulation 
conditions were varied as shown in Table 3, while the 
remaining factors were kept constant. 
Figure 3. Illustration of the effect of polymer concentration on 
the estimated mean particle size of blank HM-chitosan 
microparticles. Each point in the figure indicates a sample that was 
prepared at the specified polymer concentration and at different 
conditions of temperature, stirring speed and needle diameter, 
according to the planned experimental design. 
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Table 2. Summary table of the size responses and significant factors. 
  Significance Factor Direction 
< 2.5 μm 
Mean S Concentration - 
SD S/LOF Concentration - 
Mode NS   
Median S Concentration - 
> 2.5 μm 
Mean S/LOF Concentration + 
SD S Concentration + 
Mode S/LOF Concentration + 
Median S/LOF Concentration + 
Volume-
Median S 
Temperature + 
S=Significant; NS=Non-significant; LOF=Lack of Fit.  
Directions +/- indicate whether the factor increases or decreases the response, respectively. 
Production of naltrexone-loaded microspheres and 
drug encapsulation efficiency 
The yield of the NTX-loaded particles was generally higher 
than 85% for chitosan- and HM-chitosan microspheres, but 
significantly lower for PLGA-based particles (51-66%). The 
reason for the discrepancy is the likely formation of a high 
number of PLGA particles smaller than 0.8 μm that are 
filtered out after the emulsification-solvent evaporation 
process. Other studies have similarly shown that low 
viscosity drug/polymer solutions (such as those produced 
here for the PLGA dispersed phase), usually result in the 
formation of small particles.32
 In contrast, samples prepared from chitosan and HM-
chitosan were shown to produce viscous phases. Droplets 
formed by these polymer solutions were therefore more 
difficult to disrupt during the emulsification process, 
forming larger droplets that ultimately produced larger 
particles. These particles were easily recovered after 
filtration, resulting in higher yields.
The presence of a high drug to polymer ratio typically 
results in low encapsulation efficiencies.33,34 As a high 
drug to polymer ratio (50% w/w) was used in this work in 
order to produce particles with high drug content, this 
probably accounts for the low entrapment efficiencies 
observed for many formulations, even though higher values 
were found in some cases (Table 3).  
When chitosan was used as the polymeric matrix, the 
estimated values of EE and LC (Table 3) do not seem to be 
significantly influenced by the emulsification conditions 
(EE 42-46% and LC 14-15%). Interestingly, the 
encapsulation of naltrexone was more efficient in the 
presence of HM-chitosan, with the values of EE varying 
between formulations but being as high as 87% in the best 
case (HM-H60). The overall higher encapsulation efficiency 
in the presence of HM-chitosan is probably related to the 
higher hydrophobicity of the polymer due to the presence of 
the C12 groups. This means that in addition to the formation 
of hydrogen bonds between the hydroxyl and amine groups 
of the polymer and the hydroxyl and ketone groups of the 
drug, it is also likely that the C12 groups of the polymer form 
hydrophobic interactions with the aryl ring and cycloalkyl 
rings of the drug (Figure 1). The high affinity between the 
molecules explains the enhanced presence of naltrexone 
within the HM-chitosan microparticles, as depicted in 
Figure 4. In addition, our experiments have shown that HM-
chitosan solutions exhibit a significantly higher viscosity 
(Figure 2) than the unmodified counterpart, which can 
further reduce the diffusion of drug out of the droplets 
during emulsification.35 Another important fact is that HM-
chitosan is less soluble in water than the unmodified 
analogue. In fact, it has been shown that the lower solubility 
of the polymer in the dispersed phase causes it to precipitate 
faster, thereby contributing to increase the encapsulation 
efficiency.36 
The highest drug loading was found for the HM-H60 
formulation, where a high polymer concentration was used, 
and the solvent was evaporated at a high temperature. In this 
respect, it is generally accepted that high polymer 
concentrations also contribute to a higher encapsulation 
efficiency.36 
It should also be emphasized that the high viscosity of 1.5 
wt% HM-chitosan solutions is an indication of a high 
degree of chain entanglements and hydrophobic associations 
– acting as physical junction zones of the network –,  which 
can further account for the retention of the drug. 
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Table 3. Formulation conditions of naltrexone-loaded microspheres and encapsulation properties 
(encapsulation efficiency (EE) and loading capacity (LC)). Results shown as average ± standard 
deviation, n=3. 
 Polymer Polymer 
concentration  
(wt%) 
Temperature 
(°C) 
EE (%) LC (%) 
C-L30  
Chitosan 
0.5 30 45.9 ± 1.5 15.3 ± 0.5 
C-L60 0.5 60 44.1 ± 3.6 14.7 ± 1.2 
C-H30 1.5 30 44.5 ± 2.3 14.8 ± 0.8 
C-H60 1.5 60 42.1 ± 1.9 14.0 ± 0.6 
HM-L30  
HM-chitosan 
0.5 30 48.7 ± 1.9 16.2 ± 0.7 
HM-L60 0.5 60 64.6 ± 2.6 21.5 ± 0.9 
HM-H30 1.5 30 54.4 ± 0.2 18.1 ± 0.1 
HM-H60 1.5 60 86.5 ± 4.2 28.8 ± 1.4 
P-L5  
PLGA 
0.5 5 49.1 ± 3.5 16.4 ± 1.2 
P-L25 0.5 25 20.8 ± 2.0 6.9 ± 0.7
P-H5 1.5 5 51.0 ± 3.2 17.0 ± 1.1 
P-H25 1.5 25 52.2 ± 6.5 15.4 ± 2.7 
 It is interesting to note that the HM-H60 sample was 
prepared at a high temperature (60 °C). As mentioned 
previously, low viscosity solutions are generally obtained 
with increasing temperature, which in theory could lead to 
an increased diffusion of the drug into the continuous phase 
and a corresponding decrease in EE. Since the rheological 
measurements showed that the viscosity of 1.5 wt% HM-
chitosan solutions is only slightly affected by a temperature 
increase (Figure 2), this effect is not observed here. The 
differences between HM-H30 (prepared at 30 °C) and HM-
H60 (prepared at 60 °C) are therefore probably due to a fast 
solvent evaporation for the latter, inducing rapid particle 
solidification and limiting the diffusion of the drug to the 
Figure 4. Schematic illustration of chitosan/HM-chitosan 
networks in the presence of NTX. Within the chitosan network, 
NTX is mostly physically entrapped due to chain entanglement. 
In the HM-chitosan network, the hydrophobic intra- and inter-
molecular interactions are also very important, forming cross-
linking points due to the presence of the C12 groups. In this case, 
both the entanglements and the hydrophobic interactions are 
responsible for NTX retention. 
continuous phase. The fact that large microspheres were 
produced under these conditions may also explain the high 
EE, as observed before for other polymeric particles.37 A 
detailed interpretation of the size distribution of the NTX-
loaded particles will be given later. 
The EE of PLGA particles was mostly found in the range 
21-52%. The exceptionally low EE and LC values found for 
P-L25 (21 and 7%, respectively) are consistent with the low 
polymer concentration (0.5 wt%, and thus a very low 
viscosity) of the dispersed phase in this formulation. In 
addition, it has been shown that a fast evaporation can 
induce pore formation in PLGA microspheres,38 enabling 
the drug to diffuse out to the aqueous phase during the 
washing procedure, which further explains the low 
encapsulation of NTX. 
Morphological characterization of NTX-loaded 
formulations 
The microparticles produced in this work were generally 
spherical, as shown by SEM (Figure 5), even though 
different sizes and degrees of aggregation were obtained in 
different formulations. The micrographs showed that 
chitosan-based microparticles did not differ significantly in 
terms of size distribution and surface porosity. The detailed 
observation of samples at different magnifications showed 
the occasional presence of merged and/or irregularly-shaped 
particles in C-L30 and C-L60, suggesting that the low 
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Figure 5. SEM micrographs of naltrexone-loaded microparticles prepared from chitosan, HM-chitosan and 
PLGA. The preparation conditions of all samples are described in Table 3. Scale bar = 30 μm. 
viscosity of the polymer solution (0.5 wt%) facilitates the 
coalescence between droplets during the emulsification. 
In contrast, C-H30 and C-H60 formulations, prepared at a 
higher polymer concentration (1.5 wt%), formed stable 
droplets that resulted in well-defined microspheres. 
HM-chitosan produced very different samples depending on 
the formulation conditions.  Samples prepared at the lowest 
polymer concentration (HM- L30 and HM-L60) also 
produced irregularly-shaped particles that occurred in 
aggregates. Conversely, particles prepared at a polymer 
concentration of 1.5 wt% (HM-H30 and HM-H60) were 
shown to be spherical and well-defined, but significantly 
larger when prepared at higher temperatures (HM-H60). 
This observation is probably related with the fast solvent 
evaporation and particle solidification, as mentioned above. 
PLGA microparticles were largely polydisperse, with a high 
presence of small particles (< 3 μm). Regardless of the 
process conditions, PLGA microparticles had a porous 
surface, as shown by micrographs taken at higher 
magnifications. P-L25, particularly, showed the occasional 
presence of very large pores (up to 1 μm). P-H5 and P-H25 
samples also contained a number of rod-like particles, which 
may be related to the elongation or coalescence of droplets 
at high concentrations, in a similar way to the observations 
made by Li et al..39
Size and size distribution of naltrexone-loaded 
particles 
Figure 6 shows the size distribution of two formulations for 
each polymer and illustrates the influence of the drug  
loading on the size and size distribution of the microspheres. 
It is noticeable that, in most cases, similar size distribution 
profiles are observed both in the presence and absence of 
NTX, even though the size is shifted to slightly higher 
values when the drug is present. Moreover, the amount of 
small particles tends to decrease, while the number of large 
particles increases. This relationship between drug loading 
and particle size has been reported before.40 The increase in 
particle size in the presence of NTX may also be an 
indication of an increase in the viscosity of the dispersed 
phase, which in turn can suggest that polymer-drug 
interactions take place within the droplets. These 
interactions are probably favored by high polymer 
concentrations and temperature, as shown by the prominent 
size increase observed for C-H60 (chitosan) and HM-H60 
(HM-chitosan) formulations, in the presence of NTX.  
The size distribution of NTX-loaded microspheres prepared 
according to all formulations is depicted in Figure 7. First of 
all, it is noticeable that particles smaller than 50 μm were 
produced in most cases. Particles smaller than 2.5 μm were 
often observed in high amounts (inset plots in Figure 7) and 
it is likely that even smaller microspheres were produced 
during the emulsification, but were eliminated during the 
washing and filtration process. 
In the case of chitosan and PLGA particles, the profile 
differed slightly between formulations, but in general all the 
preparation conditions led to the production of polydisperse 
samples, with a high presence of particles in the range 5-25 
μm. The differences observed between formulations were 
not found to be statistically significant with respect to size 
and size distribution. In contrast, clear differences were 
observed between formulations prepared from HM-chitosan. 
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Figure 6. Effect of the presence of drug on the size distribution of chitosan, HM-chitosan and 
PLGA microspheres (the preparation conditions of each sample are described in Table 3). The 
solid and dashed lines represent the NTX-loaded and the blank microspheres, respectively. 
The polymer concentration was observed to play an 
important role, in agreement with the results from the 
experimental design for the blank microparticles (Figure 3).  
In general, the conditions used in HM-L30 and HM-L60 
formulations yielded smaller particles with profiles 
comparable to chitosan and PLGA. This is possibly related 
to the lower viscosity of the dispersed phase (Figure 2). 
However, the size distribution of these samples also shows 
the presence of larger structures (up to 50 μm in HM-L30 
and 100 μm in HM-L60) that are possibly large aggregates, 
as shown by SEM (Figure 5). 
The formulations that stand out compared to the others are 
HM-H30 and HM-H60, which produced microparticles with 
sizes up to 200 and 350 μm, respectively, in agreement with 
the high viscosity of 1.5 wt% HM-chitosan solutions. This 
implies that the droplets of the dispersed phase are difficult 
to divide by the shear forces. The largest particles were 
obtained at higher temperatures (HM-H60), which explains 
the higher loading capacity of the particles in this case 
(Table 3). As discussed above, the viscosity of 1.5wt% 
solutions of HM-chitosan is largely unaffected by 
temperature (Figure 2). For this reason, the large size and 
EE may be due to the fast solidification of the particles at 
the high temperature used during the emulsification step. 
In vitro drug release studies
The in vitro release profile of NTX from the different types 
of polymeric microparticles is shown in Figure 8. Chitosan 
microparticles generally showed a pronounced burst release 
during the first 6 hours – 55 to 69% of the drug was released 
within this period –, followed by a second stage, where the 
drug was slowly released or remained virtually constant 
over time. The initial burst release is quite commonly 
observed in controlled drug delivery systems that are unable  
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 Figure 7. Size distribution of naltrexone-loaded microparticles 
prepared from chitosan, HM-chitosan and PLGA. The inset shows 
the number of particles smaller than 2.5 μm. Samples were 
prepared as described in Table 3.  
to retain the drug located at the surface of the particles. The 
constant release stage that follows, reflects a slower release 
of the drug, which is usually caused by both diffusion 
through the matrix and degradation of the polymer.31  
A substantial reduction in the initial burst release was 
observed for HM-chitosan microparticles. In this case, only 
23 to 40% of NTX was released within the first 6 hours, 
depending on the formulation. After this initial release, 
NTX was very slowly and continuously released for more 
than 50 days. Only 13-26% of the total drug content was 
released during this time period, which suggests that HM-
chitosan microparticles can constitute promising carriers in 
long-term applications. The slower release rate is probably 
related to the presence of the C12 groups. These hydrophobic 
groups can act as cross-linkers due to the hydrophobic 
associations. In addition, stronger polymer-drug interactions 
are expected, as discussed previously (Figure 4). The 
presence of the hydrophobic groups is probably also causing 
a lower water penetration. 
Particles prepared according to HM-L60 and HM-H60 
conditions showed a very similar release profile and the 
slowest in vitro release rate. Interestingly, these samples 
were very different in terms of size distribution (Figure 7) 
and morphology (Figure 5). However, both of them were 
prepared at a high temperature (60 °C), and it is likely that 
the fast solvent removal resulted in a rapid solidification of 
the droplets. It may further be hypothesized that at the same 
time that the solvent evaporated, the extent of hydrophobic 
associations increased, prompting the formation of a dense 
network with limited possibilities for drug diffusion. 
Conversely, the slow evaporation rate used to prepare HM-
L30 and HM-H30 microparticles may have induced the 
formation of more porous structures. Similar findings have 
been reported for microspheres based on a hydrophobic 
dextran derivative.41 In that study, particles prepared at a 
lower solvent evaporation rate were formed slowly, and 
demonstrated large pores and cracks at the surface. These 
microspheres were shown to release the drug faster than the 
microspheres prepared at higher temperatures.41
In the case of HM-chitosan microparticles, the formation of 
compact, low porosity particles seems to be a decisive factor 
when it comes to the drug release rate, while particle shape, 
aggregation status and size distribution seem to be less 
important. However, it should be stressed that the 
differences in morphology and size between the samples 
may cause them to have different fates in vivo.26  
Finally, PLGA microspheres showed a very low burst 
release, followed by a continuous drug release that reached 
72-94%, depending on the formulation, within 16 days. 
PLGA-based controlled delivery systems have been 
extensively investigated, due to the polymer’s 
hydrophobicity, long-term stability, and its biocompatibility 
and biodegradability.42,43 In this work, we used PLGA with 
a LA/GA composition of 50:50, since this is the most 
commonly used PLGA composition in drug delivery.43
However, this copolymer also degrades relatively fast, and 
other compositions may be employed for improved polymer 
stability.43,44 After the second day, drug release levels from 
PLGA microparticles were comparable with those observed 
for HM-chitosan, while the latter provided a slower release 
rate at longer times. 
In spite of the different conditions used to produce the 
PLGA microparticles, similar release profiles were observed 
for three of the formulations, namely P-L5, P-H5 and P-
H25. These results are explained by the similar EE and LC 
(Table 3) and similar size distribution (Figure 7) between 
these  samples. The  rate  of  NTX  release was  significantly 
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Figure 8. Influence of the microparticle preparation conditions on the in vitro release of naltrexone. 
Error bars= max/min values, n=2. The preparation conditions are described in Table 3. 
lower for particles prepared according to P-L25. This is 
probably due to the low drug loading of these particles 
(Table 3). For poly(L-lactide) (PLA) microspheres 
containing NTX,45 decreasing the drug content similarly 
resulted in a significant reduction in the drug release, due to 
the lower presence of NTX at the surface of the particles. In 
the case of P-L25, the processing conditions had an
important influence on this outcome. The low polymer 
concentration and the fast evaporation rate formed a number 
of large pores at the surface of the particles, as discussed
before. As a consequence, a high amount of NTX was 
probably eliminated from the surface during the particle 
washing step, which accounts for the low EE. The low 
presence of drug at the surface of the microparticles also 
explains the reduced burst release in this case.  
In summary, this study revealed the potential of HM-
chitosan for long-term drug delivery applications. HM-
chitosan microparticles demonstrated improved controlled 
delivery properties in relation to the samples prepared with 
the unmodified counterpart. PLGA microparticles revealed 
the lowest burst effect, but subsequent drug release was 
significantly faster than for HM-chitosan. The faster release 
of NTX from PLGA particles is probably due to the 
hydrolytic cleavage of the polymer’s ester bonds.46 From 
HM-chitosan microparticles, the slower release rate suggests 
that the drug is mostly released by diffusion, to the external 
medium. 
It is important to note that the drug release kinetics may 
differ in vivo. Chitosan is known to be hydrolytically 
degraded by enzymes present in human body fluids, such as 
lysozyme47,48 and N-acetyl-ȕ-D-glucosaminidase.47 For 
injectable formulations, it has also been suggested that 
chitosan  nano- and micro-structures  may  be taken up  and 
degraded by macrophages.48 The degradation rate is also 
known to depend strongly on the degree of acetylation of 
the polymer.47,48 In a study on the oral delivery of insulin,  
chitosan particles were shown to be enzymatically degraded 
over time in simulated fluids containing pepsin, trypsin or 
chymotrypsin.49 Interestingly, an HM-chitosan derivative 
containing succinyl and lauryl moieties revealed improved 
drug protection properties and drug release characteristics in 
relation to the native chitosan.49
With respect to our work, it is similarly expected that the 
presence of C12 groups in HM-chitosan provides the 
polymer with enhanced drug delivery properties in vivo, due 
to a higher mechanical strength and resistance to enzymatic 
activity and hydrolysis. 
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CONCLUSIONS
HM-chitosan and chitosan microparticles were 
manufactured in higher yields than PLGA microparticles. 
HM-chitosan particles showed a higher encapsulation 
efficiency of NTX. The encapsulation efficiency was further 
improved when high polymer concentrations were used, and 
when the solvent was evaporated at high temperatures. In 
addition, the drug loading caused the number of small 
particles to decrease and the amount of large particles to 
increase, in comparison with the blank microparticles. In 
most cases, particle size was smaller than 50 μm, with a 
large number of small particles produced when PLGA was 
used as the matrix.  
HM-chitosan microparticles showed a significantly higher 
controlled delivery capacity than chitosan microparticles. It 
is hypothesized that this is due to the presence of the 
hydrophobic groups that limit the water diffusion through 
the pores, act as physical junction zones in the network, and 
promote strong interactions with the drug molecules. The 
release rate of HM-chitosan particles was even lower when 
the particles were prepared at higher temperatures, 
suggesting that compact structures of low porosity are 
formed under these conditions. PLGA particles showed a 
markedly lower burst release in the first hours. However, 
after a few days, these were shown to be less able to control 
drug release, as compared to HM-chitosan microparticles. 
In conclusion, the results from this study indicate that HM-
chitosan can be a promising material for a sustained delivery 
of drugs such as NTX. 
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